ANNUAL
REPORT &
ACCOUNTS
2021
BONE
CANCER
RESEARCH TRUST
UNTIL THERE'S A CURE

## **CONTENTS** 

**03** Vision / Mission / Values 

**04** Chairman’s Introduction 

**05** Income & Spend 

**06** 2021 in Numbers 

**07** Research 

**12** Information 

**14** Awareness 

**16** Support 

**20** Our Fundraising Approach 

**22** Thank You 

**23** Reference and Administrative Details 

**24** Report of The Trustees 

**29** Report of the Independent Auditors and Financial Statements 


ANNUAL REPORT AND ACCOUNTS **2021** 

**02** 



**OUR VISION** A WORLD WHERE PRIMARY BONE CANCER IS CURED 

**OUR MISSION** TO SAVE LIVES AND IMPROVE OUTCOMES FOR PEOPLE AFFECTED BY PRIMARY BONE CANCER 

## **OUR VALUES** 

- **PIONEERING** WE LEAD THE WAY, WE LEAVE NO STONE UNTURNED, WE ARE PREPARED TO TAKE RISKS. 

- **DYNAMIC** WE DON’T STAND STILL, WE INNOVATE, WE CELEBRATE EVERY SUCCESS. 

- **SUPPORTIVE** WE LISTEN, WE UNDERSTAND, WE CARE. 

- **KNOWLEDGEABLE** WE KNOW OUR STUFF, WE ARE EAGER TO KNOW MORE. 

- **TRUSTWORTHY** WE DO WHAT WE SAY. 




## **CHAIRMAN’S INTRODUCTION** 

Welcome to our 2021 Annual Report & Accounts, an extra special report that not only summarises our annual performance but the performance of our 15th anniversary year. 

2021 was yet another year where the primary bone cancer community stood by our side and allowed us to do more than ever before. We passed new records as a charity, which would be brilliant in any year, but these were ever more extraordinary in the wake of the COVID-19 pandemic. 

We started 2021 determined to return our activities to prepandemic levels. Our ambition was to invest over £1million into new pioneering research projects. And, thanks to the continued record-breaking success of our fundraising, we were able to do just that – we spent over £1.4million on research, far more than ever before. Since 2006, we have now awarded over £5million in research grant funding. We also generated new levels of interest in primary bone cancer research, with record numbers of funding enquiries and applications being received. 

Our awareness work reached new audiences and we continued our Awareness Initiative for a second year, focussing efforts on continued GP training and education of Dental Healthcare Professionals. Our campaigning drove record levels of individuals accessing our website information pages and in total, our messaging was seen over 57 million times across the UK. Our work was even externally recognised, receiving the first prize Advocacy in Action Award from SPEAN (Sarcoma Patients EuroNet). 

Throughout the year we continued to see increasing pressures and challenges hitting our patients and their families, exacerbated by the impact of the COVID-19 pandemic. Our Support & Information Service continued to adapt to the emerging needs of our community, holding 68 online virtual events, introducing face to face events again and re-introducing the Bone Cancer Conference in virtual form. In all, our service had over 1,600 contacts with patients and their families, our highest ever usage. 

Enabling all our work was you, our community of incredible supporters. You took on new levels of personal challenge and gave your time and funds to ensure that our life-saving work could continue and maintain pace. The record-breaking levels of fundraising we were able to achieve has ensured that our planned work and activities into next year and beyond can go ahead. I am always inspired by the selfless drive and determination of our wonderful community, and we cannot thank you enough for your continued efforts. 

Looking to the future, we asked you for your views on what our priorities and focus should be. We listened to your feedback and started planning the future activities of our charity beyond our current strategic period ending in 2022. I am delighted to say these plans will be launched in October 2022, as part of Bone Cancer Awareness Week. 

In preparing for the future, it is essential that we are correctly structured and equipped to maintain our trajectory of change. In recognition of our new needs, scope and scale, we appointed a new Chief Executive Officer in November, Mat Cottle-Shaw. Mat will spearhead our efforts and lead our incredible Staff Team to achieve our future ambitions. He will also ensure the needs of our patients and community are put at the heart of all we do. 

I am so proud of where we are today as a charity. As an organisation that relies almost entirely on public donations to continue our vital work, I feel a new sense of hope whenever we fund a new research project, complete an awareness campaign, or support another patient when they need it most – and it is all thanks to you! Whilst ever we have your continued support, we will be here… Until there’s a cure. 


Andy Lewis Chairman 



ANNUAL REPORT AND ACCOUNTS **2021** 

**04** 



## **INCOME & SPEND** 

## Our income in 2021 totalled **£4,673,023** . This came from: 



**----- Start of picture text -----**<br>
2%  Individual Giving<br>4%  Corporate, Trusts & Foundations<br>1%  In Memoriam<br>27%  Major Donor<br>19%  Community<br>45%  Challenges & Events<br><1% [Gaming & Shop]<br>1%  Investments<br><1%  Government Furlough Grant<br><1% [Legacy]<br>**----- End of picture text -----**<br>


Our total expenditure in 2021 was: **£2,828,865** 


**----- Start of picture text -----**<br>
A CLOSER LOOK AT OUR CHARITABLE SPEND<br>4%  Information<br>24%  Awareness<br><1%  Governance 66%  Research<br>70% 6%<br> Charitable Activities  Support<br>30%  Fundraising<br>**----- End of picture text -----**<br>


During 2021 a further £2,620,000 (not included in the charts above) was committed to planned research and awareness campaigns due to take place from 2022 onwards. 

**FOR EVERY £1** above) was committed to planned research and awareness campaigns due to take place from 2022 onwards. **WE SPENT ON FUNDRAISING £8.20 £8.20 WAS RAISED THIS TAKES THE AMOUNT THAT WE HAVE COMMITTED TO CHARITABLE ACTIVITIES IN 2021 TO £4,865,838 FOR OUR LIFE-SAVING WORK** 


ANNUAL REPORT AND ACCOUNTS **2021** 

**05** 



## **2021 IN NUMBERS** 

|57,655,490<br>5,714,000<br>4,673,023<br>3,985,749|Our awareness and campaigning activities were seen**57,655,490**times<br>2,857 individuals completed**5,714,000**burpees as part of their fundraising<br>We raised a record-breaking**£4,673,023**for our vital work<br>561,909 individuals accessed**3,985,749**pages on our website|
|---|---|
|3,500,000|Bone Cancer Awareness Week reached over**3.5 million**individuals across the UK|
|1,490,936<br>1,488,570<br>318,340<br>246,662<br>208,729<br>147,641<br>74,796<br>13,000<br>14,491<br>6,013<br>5,154<br>1,600<br>1,100<br>1,080<br>126|We spent**£1,490,936**on research – more than ever before!<br> **1,488,570**miles were cycled, ran, or walked in support of our work<br>Our patient stories were accessed**318,340**times as a source of information and support<br>Our dedicated information pages were accessed**210,405**times<br>Our social media followers grew to**208,729**from around the world<br> **147,641**donations were received from 68,731 amazing people<br>Our symptoms information page was accessed**74,796**times<br>Over**13,000**individuals took on challenges and proactively fundraised to support our<br>life-saving work<br>Our information resources were downloaded**14,491**times<br> **6,013**individuals signed up to collect stamps as part of our Stamp Appeal<br>**5,154**education materials were downloaded as part of our Bone Cancer Awareness Initiative<br>Our Support & Information Service made over**1,600**contacts<br>**1,100**individuals had joined our 9 digital support groups<br>Our Step-By-Step Guide for Patients was downloaded**1,080**times<br>We awarded**126**Financial Assistance Grants to patients|
|99|We reached**99**research grants being awarded since 2006|
|96|Up to**96%**of primary bone cancer patients are now being approached to donate tissue<br>samples for use in research.|
|68|We held**68**in-person and virtual support events|
|6|Because of the support of our community, we awarded**6**extra research projects|
|2|We held**2**research symposiums|
|1|**1**incredible community made all of this possible – our supporters.|




ANNUAL REPORT AND ACCOUNTS **2021** 

**06** 



**STRATEGIC OBJECTIVES & ACHIEVEMENTS RESEARCH** 


In line with our strategy, The Biggest Ever Commitment To Primary Bone Cancer, in July 2017 we launched our new 2017 – 2022 Grant Programme. The below table demonstrates the progress of this programme to date: 

## **2017-2022 Grant Programme** 


**----- Start of picture text -----**<br>
GRANT TYPE/YEAR 2017 2018 2019 2020 2021 2022<br>CLINICAL / TRANSLATIONAL ✓ ✓<br>EARLY CAREER FELLOWSHIP ✓<br>PHD STUDENTSHIP ✓✓ ✓ ✓<br>✓✓  ✓✓✓  ✓✓✓  ✓✓✓  ✓✓✓<br>INFRASTRUCTURE GRANTS<br>✓✓ ✓✓ ✓✓ ✓✓ ✓✓<br>EXPLORER ✓✓ ✓ ✓✓ ✓ ✓✓✓ ✓<br>IDEAS ✓✓ ✓ ✓✓ ✓✓✓ ✓✓✓ ✓<br>LARGE RESEARCH PROJECT ✓✓<br>OTHER RESEARCH INVESTMENT ✓ ✓ ✓ ✓ ✓ ✓<br>**----- End of picture text -----**<br>


✓ AWARDED AS PLANNED ✓ ADDITIONAL UNPLANNED AWARD ✓ CALL CANCELLED DUE TO ADDITIONAL PHD STUDENTSHIP ✓ PLANNED ✓ GRANT AWARD DEFERRED TO 2021 ✓ GRANT AWARD DEFERRED TO 2021 DUE TO COVID-19 DISRUPTION ✓ GRANT AWARD DEFERRED TO 2022 DUE TO COVID-19 DISRUPTION 

ANNUAL REPORT AND ACCOUNTS **2021** 

**07** 



**STRATEGIC OBJECTIVES & ACHIEVEMENTS RESEARCH** 

## **New Grants awarded in 2021** 


**----- Start of picture text -----**<br>
LEAD RESEARCHER PROJECT TITLE GRANT TYPE AWARD VALUE<br>**----- End of picture text -----**<br>


|**LEAD RESEARCHER**|**PROJECT TITLE**|**GRANT TYPE**|**AWARD VALUE**|
|---|---|---|---|
|||||
|Professor Adrienne<br>Flanagan|Sample Collection Support Grant - Stanmore (Y4)|Infrastructure|£28,396|
|Mr Jonathan<br>Stevenson|Sample Collection Support Grant - Birmingham (Y4)|Infrastructure|£29,897|
|Mr Kenneth Rankin|Sample Collection Support Grant - Newcastle (Y4)|Infrastructure|£16,000|
|Dr Sandra Strauss|ICONIC: Improving outcome through Collaboration<br>in OsteosarComa (Stage 2)|Clinical<br>Translational|£175,000|
|Professor Aykut Uren|2nd Generation Clofarabine derivatives as CD99<br>inhibitors|Explorer|£70,000|
|Professor Gareth Veal|Optimising the Treatment of Teenagers and Young<br>Adults with Ewing Sarcoma through an Increased<br>Understanding of Clinical Pharmacology and Toxicity<br>Biomarkers|Explorer|£145,530|
|Professor Susan<br>Burchill|International collaboration to optimise the<br>management of patients with Ewing sarcoma|Explorer|£149,622|
|Dr Darrell Green|_TP53_restoration using mRNA vaccine technology|Ideas|£20,000|
|Dr Karan Shah|Delineating the role of hypoxic extracellular vesicles in<br>pulmonary metastasis of osteosarcoma – a pilot study|Ideas|£19,867|
|Dr Kogularamanan<br>Suntharalingam|Bone-seeking metal-based drugs to overcome<br>chemotherapy-resistant osteosarcoma sub-<br>populations|Ideas|£20,000|
|Professor Sibylle<br>Mittnacht|Developing genome-informed treatment to improve<br>outcome in Osteosarcoma|Large Research<br>Project|£249,204|
|Dr Olivier Pardo|Modulation of interferon gamma-mediated signalling<br>and immune response by fbroblast growth factor 2<br>in osteosarcoma|Large<br>Research<br>Project|£249,781|
|Dr Martin Pule|Towards Engineered T Cells for Osteosarcoma<br>(Year 1 Award)|PhD<br>Studentship|£34,614|



Projects receiving additional funding to continue progress 

|**LEAD RESEARCHER**|**PROJECT TITLE**|**GRANT TYPE**|**AWARD VALUE**|
|---|---|---|---|
|Professor Robert<br>Falconer|Development of a targeted methotrexate prodrug<br>with enhanced therapeutic index for osteosarcoma|PhD<br>Studentship|£16,626|
|Professor Alison<br>Gartland|The Role of Oestrogen in Chondrosarcoma Using<br>Patient-Derived Xenograft Mouse Models: A Pilot study|Ideas|£16,667|



Collaborative projects supported by Bone Cancer Research Trust 


**----- Start of picture text -----**<br>
LEAD RESEARCHER PROJECT TITLE AWARDED TO AWARD VALUE<br>**----- End of picture text -----**<br>


|**LEAD RESEARCHER**|**PROJECT TITLE**|**AWARDED TO**|**AWARD VALUE**|
|---|---|---|---|
|||||
|Dr Sandra Strauss|Improving outcome in Sarcoma through Analysis and<br>interrogation of National Cancer Data|Sarcoma UK|£43,082|
|Dr Sandra Strauss|Euro Ewing Consortium|University<br>College<br>London|£36,091|




ANNUAL REPORT AND ACCOUNTS **2021** 

**08** 



ANNUAL REPORT AND ACCOUNTS 2021

**STRATEGIC OBJECTIVES & ACHIEVEMENTS RESEARCH** 


2021 saw laboratories return to normal working practices following the COVID-19 pandemic. This allowed our Grant Programme to get back on track and, for the first time in our history, we awarded over £1million in research grants to 13 projects. We also received accreditation for best practice as a medical and healthcare research charity by the Association of Medical Research Charities (AMRC) and our Infrastructure Grants where highlighted by AMRC in their impact report as best practice for collaborative research. 

As part of our 15th anniversary celebrations, we opened a unique grant call, allowing researchers to apply for funding for projects of all levels. This was our largest ever grant call and proved to be a tremendous success with 25 applications being received. Throughout the year, we received 40 applications for funding - more than ever before. This upward trend is an excellent sign that our reputation continues to grow as the leading source of funding for primary bone cancer research. It also indicates more attention and priority is being paid to primary bone cancer research and we are determined to explore all possible ways to ensure the maximum amount of research can be funded for our patients. 

Following each meeting we have continued to work closely with individuals, this has resulted in new research groups and applications being formed. 

At the heart of all our research are our patients. It is essential that their views and lived experiences of primary bone cancer inform and shape the research we fund. To embed this principle further, we developed and launched our Patient & Public Involvement Panel (PPIP). By the end of the year, we were pleased to have recruited over 17 volunteers to form part of this new panel. Each member bringing a personal and unique perspective of primary bone cancer. The panel will support researchers in the development of their research applications and provide invaluable feedback and insight to the research community that would otherwise be missing. 

In response to the strength of applications we received, we were delighted to award 6 extra unplanned grants through the year. This included 2 Ideas Grant, 1 Explorer Grant, 2 Large Research Project Grants and an additional PhD Studentship. These awards marked several new milestones for our charity, being our 10th awarded PhD Studentship to date and our first ever international research grant being awarded to Professor Aykut Üren at Georgetown University in Washington DC. 

_**Being involved in PPIP has meant that I can use my knowledge and experience, as well as improve my understanding of**_ **“** _**osteosarcoma, to help source beneficial research in the treatment of this devastating disease. I feel I’m doing something positive to instigate change that will help other families directly.**_ 

In all, we awarded 13 grants in 2021, all focused on driving forward the development of new treatments for patients, supporting essential infrastructure to support wider primary bone cancer research, increasing our understanding of the disease and ensuring current essential projects can continue. A further two awards were also granted to existing researchers to continue their promising research and expand further on their progress made to date. 

Jenny Wick, PPIP member and parent of a patient. 

In addition to the creation of our PPIP, in 2021 we wanted to expand the international representation on our Independent Scientific Advisor Panel (ISAP). Through the year we were delighted to welcome three new members: Professor Thomas Grünewald, Dr Nathalie Gaspar and Dr Didier Surdez. Together they add representation and knowledge from Germany, France and Switzerland. We thank all our ISAP members for their invaluable support and dedication to the progression of primary bone cancer research. 

During the year we opened applications for our first ever Early Career Fellowship. This is a key award of our 2017 – 2022 Grant Programme as it represents our largest ever grant designed to support an upcoming researcher develop their own programme of research in primary bone cancer. We also launched The Hamilton Osteosarcoma Research Programme, a dedicated and unexpected £1million research programme dedicated to the development of osteosarcoma treatments. Both of these exciting projects will be awarded in 2022. 

Further milestones during the year also included our first ever award to support consortia. We were delighted to partner with the Ewing’s Sarcoma Research Trust to fund the EURO EWING Consortium, a group that remains pivotal to the development of future international clinical trials and collaborative research in Ewing sarcoma. ICONIC, our first ever funded clinical trial, surpassed recruitment of 100 osteosarcoma patients. During the year we awarded the second phase funding of the ICONIC project which continues to be the only project of its kind for osteosarcoma patients of all ages in the UK. 

As part of our research strategy, we are commitment to facilitating and generating collaboration wherever possible. Highlights of the year included our second International Ewing Sarcoma Research Symposium and our second Osteosarcoma Symposium.The meetings were incredibly successful, attracting international attendance and generating new ideas and areas of interest for potential future research. 




ANNUAL REPORT AND ACCOUNTS **2021** 

**10** 



## **2017-2022** 

## **WHAT WE SAID WE’D DO & WHAT WE DID...** 

We will commit over £2.8 million to pioneering research through an innovative new grant programme. Our total investment into pioneering research in 2021 was £1,490,936 which includes the award of 13 new research grants, second phase funding to 2 existing projects and supporting 2 collaborative projects. 

## **WHAT WE’RE GOING TO DO IN 2022…** 

We will support research at all levels, from initial idea through to clinical trial. 

2021 saw us fund 3 Ideas projects focusing on innovative new treatments for osteosarcoma and chordoma, 2 Explorer projects focusing on Ewing sarcoma research and the second phase of the clinical trial ICONIC. 

- **01**[  We will launch a new and ambitious  ] Research Strategy. 

- **02**[  We will proactively support researchers ] through the expansion of our Patient & Public Involvement Panel, encouraging researchers to use this invaluable resource whenever possible. 

We will deliver the next generation of world class, primary bone cancer researchers. 

During 2021 we were delighted to award our 10th PhD Studentship, bringing another talented individual into the field of primary bone cancer. We also, for the first time, awarded funding to senior post-doctoral researchers to aid their career progression in primary bone cancer research. 

- **03**[  We will  award our first programme grant, ] supporting collaborative research in osteosarcoma to improve patient outcomes. 

- **04**[  We will award our first ever Early  ] Career Fellowship. 

We will continue to support UK surgical centres to enable all primary bone cancer patients to contribute tissue samples for use in research. 

- **05**[  We will expand our existing Grant Programme ] to include new grant types, including Consortia and Skills Development Grants. 

In 2021 we were pleased to re-award Infrastructure Grants to 3 of the 5 bone cancer surgical centres in England. Two centres did not require additional funding due to awards in 2020 still remaining post-pandemic. 

- **06**[  We will promote Skills Development Grants  ] to improve knowledge and skill gaps in the primary bone cancer research community and to promote our research being shared at national and international conferences. 


- **07**[  We will continue to explore collaborations that ] will bring greater benefit to our patients. 

- **08**[  We will hold face to face symposia focused  ] on multiple primary bone cancers. 



ANNUAL REPORT AND ACCOUNTS **2021** 

**11** 



## **STRATEGIC OBJECTIVES & ACHIEVEMENTS INFORMATION** 


2021 continued to be an unusual year for our information provision. With the effects of the COVID-19 pandemic still being felt by many patients and their families, we continued to focus our efforts online to ensure even those in the most remote situations could access information when and how they needed it. We saw a 17% increase in use of our online information pages compared to 2020 with pages being accessed 246,662 times. 

To support individuals of varied ages and experiences, we held online events and webinars throughout the year. These events were dedicated to specific topics, including fear of recurrence, body image, dealing with diagnosis as a younger person and long-term survival – to name a few. 

## _**The Bone Cancer Research Trust have helped me understand more about my loved one’s diagnosis; talk through worries and access**_ **“** _**other organisations who may be able to help us.**_ The wife of a current patient 

A key highlight was the development of our new video resources dedicated to helping those who may be facing or have had an amputation. We worked with focus groups to ensure the videos would be as effective as possible. This resulted in 9 videos being produced, each focusing on different aspects. Each video was delivered by former patients and healthcare professionals with lived experiences of primary bone cancer. The videos were made available online in November and had been watched 1,587 times by the end of December, we continue to receive positive feedback about them and are exploring potentially similar videos in the future. 

During the year we started to review our all our information. We launched newly revised online webpages mid-year and expanded our information to also provide a dedicated page on the symptoms of primary bone cancer, this page was accessed 74,796 times in 2021 – our highest ever accessed information page. 

We continued to make available and distribute our factsheets to patients, healthcare professionals and all those involved in a primary bone cancer journey. In all, 2,868 were distributed and a further 1,675 guidance pages on specific bone cancer surgical centres were also shared. 

## _**They have accurate information on what I need. I feel I can ask as many questions as I need to.**_ **“** A healthcare professional 

At the Bone Cancer Research Trust, we continue to be the only organisation offering dedicated information covering all forms of primary bone cancer and tumour. The below chart demonstrates the usage of this information by tumour type: 



**22071** Spindle Cell Sarcoma of the Bone **12297** Ewing sarcoma **13062** Chondrosarcoma 

- **10491** Giant Cell Tumour of the Bone 

   - **7919** Angiosarcoma of the Bone 

**6499** Ameloblastoma 

- **3113** Osteosarcoma 

**3285** Adamantinoma 

**1831** Chordoma 


ANNUAL REPORT AND ACCOUNTS **2021** 

**12** 



## **2017-2022** 

## **WHAT WE SAID WE’D DO & WHAT WE DID...** 

We will develop a Patient / Parent Pack to offer comprehensive information to all patients on their specific primary bone cancer or tumour type. 

We continued to promote our highly successful StepBy-Step Guide for Patients. This invaluable resource was accessed over 3,500 times throughout the year. 

We will develop information for carers and families of patients with primary bone cancer. 

Through our Support and Information Service we continued to provide direct information and support to carers and family members of patients through our Support & Information Line and our online and offline events. 

## We will expand our existing portfolio of information for patients of all ages. 

Our new amputation resources are aimed at patients of all ages and have been developed as a series of short videos to make these easily digestible. 

Our dedicated Children’s resources continued to see popular demand for those seeking to help educate and support younger patients, Harry has an Operation was downloaded 798 times and Abbie has Osteosarcoma was downloaded 636 times. 

We will expand our basic information to ensure patients in other countries have access to relevant information. 

Our information was shared with Sarcoma Patients EuroNet (SPAEN) to allow access by patients across Europe. Our symptoms information was translated to several different languages, including Spanish, French and Italian. 

Our social media campaigns continued to promote our information throughout the UK and overseas. Our website pages were accessed over 2.5million times throughout the year from individuals in overseas countries. Top accessing countries included the Unites States, Germany, Russia, Canada and India. 

## We will ensure that information is available for the clinical and medical community. 

Our dedicated hub for healthcare professionals was accessed 1106 times and continued to provide invaluable tailored and dedicated information covering all aspects of primary bone cancer. 

We will accurately signpost relevant information that falls outside our remit. 

Our signposting hub was accessed over 886 times throughout the year, taking individuals to organisations that can offer help and serviced beyond our remit. 

## **WHAT WE’RE GOING TO DO IN 2022…** 

- **01**[  We will optimise our online information pages ] to improve accessibility and will begin work developing a new website. 

- **02**[  We will update and re-launch our Ewing ] sarcoma and osteosarcoma information booklets. 

- **03**[  We will add to our online information pages ] to include greater detail on statistics and incidence. 

- **04**[  We will apply for Patient Information Forum ] (PIF) accreditation, ensuring we meet best practice in patient information production. 

- **05**[  We will re-introduce Information Days at bone ] cancer surgical centres. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**13** 



**STRATEGIC OBJECTIVES & ACHIEVEMENTS AWARENESS** 


2021 was a record year for our public reach at the Bone Cancer Research Trust. Our campaigning activities were seen over 57 million times - a year on year increase of 73%. In addition to educating the public, we continued our efforts to educate healthcare professionals, circulating over 71,280 training resources. 

We started the year with a real highlight, receiving the first prize Advocacy in Action Award from SPEAN (Sarcoma Patients EuroNet) for the first phase of our Bone Cancer Awareness Initiative, which was completed in 2020. For Bone Cancer Awareness Week 2021 we launched the second phase of the project, this time focused on the training of dental healthcare professionals. Like GPs, dental healthcare professionals receive little-to-no training on how to spot red flag symptoms of primary bone cancer, despite 14% of cases being in the skull, face and jaw. For the campaign, we were delighted to team up with Portman Dental Care and launch a UK-wide campaign where we held online training webinars and sent education packs to 11,370 dental practices and 18 dental schools. In total, our campaign was seen 3.5million times and featured in regional broadcast media. 

To understand the current picture with primary bone cancer incidence, survival, and diagnosis, we had planned to complete an independent analysis of data held by Public Health England in 2021. However, as a charity we always strive to collaborate wherever possible and try to avoid duplication of efforts with life-minded organisations. Therefore, we were pleased to combine efforts with Sarcoma UK again and begin plans for funding a joint project in this area. We are expecting this work to start in 2022. 

In February, we were delighted to collaborate with Sarcoma UK to launch a medical student survey. This crucial data helped us to understand the specific educational needs within this target group and gave rise to an ongoing joint project between our two charities. In May, we launched our joint Sarcoma Awareness Project for junior doctors and awarded seven fellowships, allowing junior doctors to undertake a placement at a sarcoma centre and learn more about how the disease is managed. The purpose of the project is to educate medical professionals earlier in their career and equip them with a greater understanding of primary bone cancer / bone sarcomas. 

CONGRATULATIONS TO ALL OUR 2021 BONE IDOLS: 

During Sarcoma Awareness Month in July, we launched a new report called 15 Years of Research – Working Towards a Cure. This inspiring piece was showcased at our 15th Anniversary Party, where examples of our work were displayed for our supporters to read. The event was a celebration like no other in our history, blending celebration with fundraising and it introduced our inaugural Bone Idol Awards. These unique and special awards recognised individuals from across the whole primary bone cancer community, from fundraisers and volunteers to researchers and surgeons. In all, 12 awards were presented on the night to outstanding individuals who really do represent the very best of our community. The awards generated media interest across the UK and brought many healthcare professionals into direct contact with our life-saving work for the first time. 

Dr Phillip Green, Professor Pam Kearns, Helen Buglass, Julie Wantling, Karen Schurer, Lee Morris, Louise & Mike Ashton, Jeremy Reynolds, Pete Lloyd, Professor Lee Jeys, Dr Sandra Strauss and Sue & Andy Collard. 



ANNUAL REPORT AND ACCOUNTS **2021** 

**14** 



## **2017-2022** 

## **WHAT WE SAID WE’D DO & WHAT WE DID...** 

We will ensure all GPs in the UK have access to the training and tools they need to identify and diagnose primary bone cancer. 

Throughout 2021 we continued to promote materials from our 2020 Bone Cancer Awareness Initiative campaign. These were accessed 6,913 times during the year and our education webinars were seen 1,904 times. 

## We will develop tools to allow radiographers, physiotherapists, and other medical professionals to identify the symptoms of primary bone cancer. 

Our wider healthcare professional materials were distributed 638 times during the year and our Bone Cancer Awareness Week campaign focused on the training of Dentists on primary bone cancers of the head and neck. In total, 71,280 training resources were sent to 11,370 dental practices across the UK. 

We will continue to fund and develop training options for medical students in the field of primary bone cancer. 

We continued to provide information and materials to medical schools throughout the UK and we welcomed 4 students from The University of Sheffield, supporting them on projects specifically related to primary bone cancer. 

We collaborated with Sarcoma UK to understand the training needs of medical students and funded the National Sarcoma Awareness Project, aimed at educating medical students and junior doctors on sarcomas. 

We will increase national and, where possible, international public awareness of primary bone cancer and the Bone Cancer Research Trust. 

## **WHAT WE’RE GOING TO DO IN 2022…** 

- **01**[  We will work collaboratively to fund a data ] analyst to capture key primary bone cancer statistics, including incidence, survival, and routes & time to diagnosis. This will inform our work on early diagnosis. 

- **02**[  We will support training fellowships for medical ] students and junior doctors to work in a sarcoma specialist centres to gain valuable and career lasting knowledge in sarcoma. 

- **03**[  We will present at the British Sarcoma Group ] meeting; highlighting the issues that our patients face with delayed diagnosis. 

- **04**[  We will formalise and expand our Healthcare ] Expert Panel and develop a strategic plan to improve the awareness of primary bone cancer amongst the public and healthcare professionals. 

- **05**[  We will launch a new 10-year strategy as part  ] of Bone Cancer Awareness Week. 

We continued to build momentum through our campaigning activity which was seen 57,655,490 times during the year. 



ANNUAL REPORT AND ACCOUNTS **2021** 

**15** 



**STRATEGIC OBJECTIVES & ACHIEVEMENTS SUPPORT** 


As the primary bone cancer community continued to navigate the COVID-19 pandemic, we also continued to react and adjust our approach to support as many people as we could. Our Support & Information Service made over 1,600 contacts with patients, family members and carers throughout the year and delivered 68 in-person and virtual support events. We also awarded £8,520 to assist patients with the financial pressures that come with a primary bone cancer diagnosis, through our Financial Assistance Grants. 

For a long time, it has been known that the additional financial pressures of a cancer diagnosis can cause added distress for patients and their families. To help alleviate some of these pressures, we launched our Financial Assistance Grants on February 4th; World Cancer Day. By the end of 2021 we had awarded 141 of these grants which have been incredibly well received by patients. 

As part of Bone Cancer Awareness Week, we held our flagship support event, the Bone Cancer Conference. Due to the ongoing impact of the COVID-19 pandemic, it was not possible to hold the event face to face, so we took the event online with a theme of ‘Reuniting our community’. For the first time ever, delegates were able to join from around the world and watch back sessions multiple times. 22 guest speakers covered subjects from prosthetics to surgery to clinical trials. 

## _**Thanks to everyone at the Bone Cancer Research Trust for being able to offer our patients some financial support. The patients are**_ **“** _**really grateful for it.**_ A healthcare professional 

_**Thank you and thank you for all the support you give us. It’s going to be vital over the next few months and it’s a huge help**_ **“** _**knowing where to find it without going looking.**_ Parent of a current patient 

Throughout the year we continued to hold our weekly ‘Virtual Cuppa’. This event has become a key aspect of our service and is regularly attended by up to 12 individuals affected by primary bone cancer. Additionally, we held tailored virtual events for younger individuals – focusing on a positive activity as a way to engage with others and share experiences. We also continued to work with Henry Dancer Days, providing Virtual Storytime to children in need of a positive escape from the reality of primary bone cancer. 

To help patients and carers navigate specific topics, we continued to hold virtual webinars. These have proven to be really successful and are being planned for 2022. 

_**“The Fear of Recurrence webinar was really good. We’ve had and will soon have a number of Teenage Young Adults finishing**_ **“** _**treatment so it’s been a really helpful watch.**_ Teenage Cancer Trust Youth Support Co-Ordinator 

_**I want to say thank you for the Virtual Cuppas this year. The way you’ve presented them has been fantastic.**_ **“** Former patient 

We know that lived experiences of primary bone cancer are an essential source of information and support for new patients. We continued to promote our Virtual Support groups throughout the year which now have well over 1,100 members sharing their experiences. We also continued to promote the sharing of personal stories. Throughout the year our patient stories were viewed 318,340 times, this is an increase of 130% compared to 2020. 




ANNUAL REPORT AND ACCOUNTS **2021** 

**16** 



## **2017-2022** 

## **WHAT WE SAID WE’D DO & WHAT WE DID...** 

We will provide a listening ear service that allows current patients or family members to talk with someone that has been through a similar experience. Our Support & Information Service made over 1,600 contacts throughout the year. 

We will develop digital ‘community’ support groups. Our 9 Digital Support Groups continue to attract new patients, family members and carers to provide a safe environment for shared lived experiences and to ask questions. 

We will deliver an annual conference aimed at uniting and supporting our community. 

The Bone Cancer Conference returned virtually in October and was attended by 52 individuals. 

We will actively promote the sharing of patient stories and experiences. 

25 new patient stories were developed and shared through 2021 and our Support & Information Service proactively brought together families and individuals with similar experiences to gain mutual support. 

We will ensure robust signposting to other support groups and charities where we cannot provide assistance. 

## **WHAT WE’RE GOING TO DO IN 2022…** 

- **01**[  We will hold two Bone Cancer Conferences at ] venues across the UK. 

- **02**[  We will commence face-to-face support ] meetings across the UK, enabling patients to gain peer-to-peer support. 

- **03**[  We will expand our Support & Information ] Service to include WhatsApp messaging, increasing our accessibility for patients. 

- **04**[  We will expand our collaboration with Henry ] Dancer Days to offer personalised 1-to-1 storytelling sessions for children affected by primary bone cancer. 

- **05**[  We will develop specific support for bereaved ] parents and families and for siblings of patients. 

Our Support & Information Team now actively signpost to 87 organisations across the UK offering help and support beyond our remit, such as counselling, legal advice, and practical assistance with matters such as travel insurance. 



ANNUAL REPORT AND ACCOUNTS **2021** 

**17** 



## **OUR SUPPORT & INFORMATION SERVICE** 

For anyone in need of information or support with any aspect of coping with or dealing with primary bone cancer – we’re here. 

The approach of our service is to be dynamic and patient-led; we aim to provide our community with an added layer of support on top of that provided by healthcare professionals, who we work hand-in-hand with. 

Our service provides: 

- A freephone Support & Information Line - 0800 111 4855 (Mon - Fri 9am - 5pm) 

- Financial assistance grants for every new patient in the UK 

- Virtual primary bone cancer & tumour support groups across the UK 

- Confidential and professional support from our dedicated team 

- Access to reliable, accurate and award-winning bone cancer and tumour specific information 

- An annual conference, bringing together our community in a supportive and safe environment 

- A library of Support & Information Webinars, covering topics pertinent to primary bone cancer 

- Dedicated digital community support groups 

- Correct signposting to organisations that can provide greater assistance 

- Access to patient stories and the opportunity to be connected with others, who have had similar experiences 


ANNUAL REPORT AND ACCOUNTS **2021** 

**18** 



ANNUAL REPORT AND ACCOUNTS 2021
19


## **OUR FUNDRAISING APPROACH** 


In 2021, 147,641 donations were made to support our life-saving work from 68,731 amazing people. Over 13,000 incredible individuals undertook a challenge or activity, from running to skydiving to going orange for the day – all to help bone cancer patients. We thank every single one of our supporters; because of them we raised a record breaking £4,673,023 to help primary bone cancer patients. 

At the Bone Cancer Research Trust, we take a relationship-first approach to all our fundraising activities, seeking to build meaningful and long-term relationships with all our supporters. We strive to ensure that anyone choosing to support our charity has the best possible experience and we continually learn from and review our activities to shape our approach in the future. 

Whilst our fundraising activities have grown in recent years, we do not employ third party fundraising organisations to work on our behalf or use methods of fundraising that can be seen as intrusive or persistent. We are also very conscientious about self-regulation of our fundraising activities and protecting vulnerable people. We are especially careful and sensitive when engaging with those affected by cancer. 

During the year, we continued to offer online and offline fundraising opportunities. Our virtual fundraising challenges continued to be a successful source of significant income and our dedicated efforts were recognised in November as we won the Best Virtual Fundraising Event Award from Fundraising Everywhere. Our offline campaigns continued to engage existing supporters of our charity and we were lucky enough to secure our second BBC Radio 4 Appeal in December, which generated over £17,000. 

The Bone Cancer Research Trust continued to be a member of the Fundraising Regulator. During 2021 we received no complaints from the regulator relating to any of our fundraising activities. 



Our continued drive to diversify our income and reduce reliance on any one income stream has allowed us to grow and significantly refine our fundraising approach. We have seen significant success in our community-based fundraising which has continued to go from strength to strength. 2021 was another year where we attracted new proactive and ongoing volunteer fundraisers to lead our Special Funds. We continue to provide personal and ongoing support, guidance, and materials to facilitate their tireless efforts. 

In April, we received our first ever donation of £1million. This incredibly generous personal donation will fund The Hamilton Programme of Osteosarcoma Research, an entirely new research programme of research dedicated to driving forward new treatments for osteosarcoma. This will be awarded in 2022. 


In all our activities we aim to ensure that our supporters and the wider public are treated fairly and with respect. We continually monitor and review our practices to ensure we are adhering to the latest in fundraising regulations and practices. The Bone Cancer Research Trust also voluntarily subscribes to the Fundraising Regulator and its Code of Fundraising Practice. All staff are aware of and adhere to Charity Commission guidelines and The Code of Fundraising Practice which sets out statutory obligations and best practice standards. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**20** 



18ERrY's
LEGACY
rN
ANNUAL REPORT AND ACCOUNTS 2021


## **THANK YOU** 

The Bone Cancer Research Trust relies almost entirely on public support to continue our life-saving work — whether this be through financial donations, fundraising, donating time, or donating skills and services. We would like to thank every single person who has supported us in 2021 – without you, we could not do what we do for primary bone cancer patients! 

## **Special Funds** 

We would like to thank all our Special Funds and their supporters for their unwavering support and dedication… 

Abigail’s Ambition, Adam Dealey, Adam Hassall Tribute Fund, Adam Panther Tribute Fund, Alexander Albiston Tribute Fund, Al Dawson Tribute Fund, Alex Lewis Memorial Fund, Anthony Pilcher Bone Cancer Trust, Ashton’s Fund, Campaigns for Caroline , Chloë’s Fight, Chris Fairley Fund, Christopher Spratt Tribute Fund, Daniel Bridle Memorial Fund, Daniel Humphreys Tribute Fund, The Darren Wilkinson Amelo Warrior Fund, Dila’s Fund, Emily Barker Tribute Fund, Fitzy’s Fund , Flora’s Fund, For the Love of Stephen, Frank’s Fund, Freddie’s Future, Gemma Pickering Tribute Fund, Guy Francis Tribute Fund, The Jack Sparrow Fund, James Stewart Tribute Fund, Jennifer Carvell Tribute Fund, Jessica Gower My Blue Heart Fund, Jordon Wilson Tribute Fund, Josh Williamson Tribute Fund, Jude’s Fund, Kenny McCabe Tribute Fund, Ken Davies Tribute Fund, Kieran’s Legacy, Krystle Smith Tribute Fund, Laura Connolly Tribute Fund, Liberty’s Legacy, Liz Clarke-Saul Fund, Lol’s Legacy, Mary Collard Tribute Fund, Matt’s Beacon Fund, Menafest, Nick Pollard Tribute Fund, Pushing for a Cure, Rhodri Jones Memorial Appeal, Ruth Grace’s Battle, Sam’s Fund, The Scott Abbruzzese Memorial Fund, Tom Stead Tribute Fund, Zack Foley Fund 

## **Our Active Ambassadors** 

Laurence Whiteley, Peter Lloyd, Dr Phillip Green, Charlene Young 

## **Corporates, Trusts and Foundations** 

Albert Gubay Charitable Foundation Balcombe Trust Barbour Foundation Clive Richards Foundation David Brooke Charity Department for Business, Energy & Industrial Strategy Ewing’s Sarcoma Research Trust February Foundation Garfield Weston Foundation Michael Davie Research Foundation Miss Margaret Butters Reekie Charitable Trust P F Charitable Trust Robert Luff Foundation Ltd 

## **Volunteers** 

Adam Bowers, Aimee Hunter, Benjamin Lang, Brenda Peel, Felicity Smith, Johnny Quinn, Julie Scorer, Terri Bush 

…as well as all the many individuals who have supported us at fundraising events and are taking part in our Stamp Appeal. 

## **Information Review Panel** 

Dr Darrell Green, Dr Elizabeth Roundhill, Dr Katrina Ingley, Dr Lucia Cottone, Dr Phil Green, Dr Sandra Strauss, Geraint Davies , Millicent Lipshaw , Mr Kenneth Rankin , Mr Muzzammil Nusrath , Pete Lloyd, Professor Bernadette Brennan , Professor Paul Cool 


ANNUAL REPORT AND ACCOUNTS **2021** 

**22** 



## **REFERENCE AND ADMINISTRATIVE DETAILS FOR YEAR ENDED 31[ST] DECEMBER 2021** 

## **Trustees:** 

Andrew Lewis (Chair until 30/4/2022) Alison Gartland (Chair from 30/4/2022) Roger Paul Gillian Elizabeth Johnston Sarah Bernadette Dawson (retired 19/1/22) Malcom Matthews (retired 5/4/21) Damien Harper James Maffin Bernadette Brennan Arlene Eves Darrell Green Jonathan Stevenson Elizabeth Eatock (appointed 23/10/21) 

## **Clerk to the Trustees:** 

Elizabeth Eatock (resigned 30/4/22) Jenny Connolley (appointed 30/4/22) 

## **Independent Scientific Advisory Panel:** 

## **Chair: Professor Pam Kearns** 

MBChB, BSC (Hons), PhD, FRCPCH, Professor of Clinical Paediatric Oncology and Honorary Consultant in Paediatric Oncology, University of Birmingham 

## **Deputy Chair: Professor Robert Brown** 

Chair in Translational Oncology, Imperial College London and The Institute of Cancer Research 

## **Lay Member: Dr Phil Green** 

Lay member of Independent Scientific Advisory Panel 

## **Principal Address** 

Unit 10, Feast Field Horsforth, Leeds, LS18 4TJ 

## **Registered Charity Number** 

1159590 

## **Senior Management Team** 

Mr M Cottle Shaw – CEO Mrs Z Davison – Head of research and information Mrs C Taylor – Head of finance Mrs L Riach – Head of fundraising and communications (appointed 22/3/22) 

## **Independent Auditors** 

Thomas Coombs Limited Statutory Auditor, Chartered Accountants 3365 The Pentagon, Century Way Thorpe Park, Leeds West Yorkshire, LS15 8ZB 

## **Bankers** 

CAF Bank Ltd 25 Kings Hill Avenue, Kings Hill West Malling, ME19 4JQ 

Lloyds Bank 65-68 Briggate, Leeds West Yorkshire, LS1 6LH 

**Member: Piers Gaunt** 

BSc MSc, Senior Biostatistician, University of Birmingham 

## **Member: Dr Paulo Ribeiro** 

BSc MSc PhD, Senior Lecturer and Group Leader, Bart’s Cancer Institute 

## **Member: Professor Thomas Grünewald** 

MD, Division Head, Translational Paediatric Sarcoma Research, German Cancer Research Center, Heidelberg, Germany 

## **Member: Dr Nathalie Gaspar** 

Paediatric Oncologist, Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, France 

## **Member: Dr Didier Surdez** 

Senior Researcher in the lab of Olivier Delattre, Institut Curie, Paris 

## **Solicitors** 

Shakespeare Martineau Waterfront House 35 Station Street Nottingham NG2 3DQ 

## **HR Consultants** 

The HR Dept Ltd First Floor 3 Brook Office Park Emersons Green Bristol BS16 7FL 

## **Investment Managers** 

Brewin Dolphin 10 Wellington Place Leeds, LS1 4LX 


ANNUAL REPORT AND ACCOUNTS **2021** 

**23** 



## **REPORT OF THE TRUSTEES FOR YEAR ENDED 31[ST] DECEMBER 2021** 

The trustees present their report with the financial statements of the charity for the year ended 31st December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). 

## **Objectives And Activities** 

## **Objectives and Aims** 

The Bone Cancer Research Trust (BCRT) became a Charitable Incorporated Organisation (CIO) on 1st January 2015 and is a trust that is governed by a Trust Deed and managed by a Board of Trustees. The Constitution states that the object of the CIO is the relief of sickness generally and in particular, but not so as to limit the generality of the foregoing: 

## **i) promoting research into the causes and treatment of primary bone cancer and publishing useful results thereof; and ii) providing support and information services for persons suffering from primary bone cancer and their treatment.** 

She is a NCRI Sarcoma Chair and member of the YOSS, Bone and STS subgroup, she chairs the CCLG (Childhood Cancer and Leukaemia Group) Rare Tumour Group and is a member of EXPeRT European Rare Tumour Group. She has given a number of invited lectures for learned societies and research groups both in the UK and overseas. 

## **Sarah Dawson** 

Sarah is a Coach and HR Training Consultant who became a trustee after her son Al died in November 2007. Sarah lectures on related topics and spreads awareness of primary bone cancer to a wide range of audiences including students in nursing and other allied healthcare professionals. 

## **Arlene Eves** 

Our vision is a world where primary bone cancer is cured. Our mission is to save lives and improve outcomes for people affected by primary bone cancer by being: 

- The catalyst for pioneering research 

- The trusted source of information 

- The voice of the primary bone cancer community 

- A supportive network for the people affected. 

The trustees have complied with the duty set out in Section 4 of the Charities Act 2011 and have paid due regard to the public benefit guidance published by the Charity Commission. 

## **Board Of Trustees** 

## **Andy Lewis - Chair** 

Andy has 40 years’ experience in technology, project management and consultancy. He has worked as a Founding Board Member (BBC Technology), a Company Director and a Programme Director (NCR, BBC, Siemens, ITV, Coopers and Lybrand, Sainsburys, RBS). Andy’s son, Alex, passed away from Osteosarcoma in February 2011. 

## **Roger Paul - Deputy Chair** 

Roger’s business life was in telecommunications, working in an executive position with AT&T. His daughter, Claudia, died at the age of 17, following a three-year battle with Ewing sarcoma. Her final wish was for Roger to help children in her position in the future, and consequently, he has been a trustee for 10 years. 

Arlene is a pensions lawyer experienced in advising trustees of occupational pension schemes. She joined BCRT as a trustee in 2018. 

## **Gillian Johnston** 

Gill has 40 plus years’ experience in bookkeeping, payroll and general administration. Her son, Anthony, passed away following a battle with Osteosarcoma in October 2002, and she was a founding trustee of BCRT. 

## **James Maffin** 

James is a finance professional and an associate member of the Chartered Institute of Management Accountants. He is Chief Financial Officer for an award-winning manufacturing business. 

## **Malcolm Matthews** 

Malcolm has experience as a charity trustee and 25 years as a director at national charities. He had leadership roles providing services and information, creating policy, campaigning and fundraising. He became involved with BCRT after his youngest son died in 2007 as a result of a Ewing sarcoma that was misdiagnosed. 

## **Jonathan Stevenson** 

Jonathan is a Consultant in Orthopaedic Oncology at the Royal Orthopaedic Hospital, Birmingham, managing adult and paediatric bone and soft tissue tumours of the limbs and pelvis. He became involved with BCRT in 2019 to help promote research and awareness. 

## **Bernadette Brennan** 

Bernadette is a Professor in Paediatric Oncology and Consultant Paediatric Oncologist at Royal Manchester Children’s Hospital and The Christie NHS Foundation Trust. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**24** 



## **Darrell Green** 

Darrell’s best friend passed away from primary bone cancer when they were teenagers. Darrell is now a Lecturer and Researcher at Norwich Medical School, University of East Anglia. Darrell trained in molecular genetics at Addenbrooke’s Hospital in Cambridge before obtaining his PhD in molecular biology at UEA. His research combines genetics, cell and molecular biology with bioinformatics to study gene silencing in primary bone cancer. Darrell sits on the editorial board of scientific journals and on grant review panels for other cancer charities. He is a member of Norwich Cancer Research Network. He has appeared several times on TV and Radio and has presented his research across the UK and in the USA. In 2019, he was listed as a Universities UK Top 100 People “The Nation’s Lifesavers”. In 2020, Darrell joined BCRT as a trustee. 

## **Damian Harper** 

Damian was diagnosed with Osteosarcoma in 1986 at just 17 years old. He has had a successful career, initially as a biomedical scientist, working in a pathology laboratory, then moving into project and programme management. 

## **Alison Gartland** 

Alison is a Professor of Bone and Cancer Biology at The University of Sheffield and has a background of over 20 years of research into bone biology including primary bone cancer. Alison currently heads up a team of researchers looking at mechanisms of primary and metastatic bone diseases and is regularly involved in education of Medical Students at The University of Sheffield. As such Alison has knowledge of the current research landscape and also the medicine curriculum and teaching priorities for the doctors of the future. Alison is passionate about raising awareness about primary bone cancer. 

## **Sub-Committees** 

The Management and Finance Committee has delegated responsibility for overseeing financial, strategic and HR matters, and also acts as the remuneration committee, making recommendations to the Board of Trustees in respect of employee salaries. The Management and Finance Committee meets at least 4 times per year. The committee members in 2020 were: 

- Gillian Johnston (Committee Chair) 

- Andy Lewis 

- Roger Paul 

- James Maffin 

## **Recruitment and Appointment of New Trustees:** 

The CIO constitution requires the Board of Trustees to have at least 8 members. BCRT reviews the skills mix of the existing Board when recruiting new trustees, to ensure that their skills, personal and professional experiences are complementary to the existing board. On their appointment, new trustees are provided with, or have online access to the following documents: 

- Latest audited Annual Report and Statutory Accounts 

- Management accounts for the current year 

- Minutes of trustee meetings for the current year 

- BCRT’s conflict of interest policy 

- BCRT’s financial procedures 

Following their appointment, new trustees have a planned induction process during which they meet the staff team, spend time with other trustees, and get to know more about BCRT’s activities. Trustees serve a 3-year term, after which they are eligible for re-election. 

During 2019, a recruitment process was undertaken to appoint additional trustees with specific skills, which complemented the existing trustee board. The opportunity to become a trustee was advertised widely, on social media, the BCRT website and by relevant industry bodies. Recruitment took place towards the end of the year, and the successful applicants were appointed at the start of 2020. 

## **Organisational Structure** 

The Board of Trustees meets at least 4 times a year to set the strategic direction of the charity, review ongoing operational and financial performance, approve the awarding of new research grants, and review the risks faced by the charity. The Trustees give their time freely and no trustee remuneration was paid during the year. Details of trustee expenses and related party transactions are disclosed in notes 10 and 24 of the accounts. Responsibility for the day-to-day running of the charity is delegated to the Chief Executive Officer, who is supported by a Senior Leadership Team, which comprises: 

• Head of Fundraising and Communications 

- Head of Research, Information and Support 

- Head of Finance 

The pay of the Chief Executive Officer and Senior Leadership Team is benchmarked against appropriate roles in similar charities. The charity is committed to achieving a balance between paying market rates to attract the most competent staff, and careful management of funds. A policy for staff remuneration is in place and applies to all staff employed by the charity. 

The total number of staff employed at 31 December 2021 was 22 (including 7 who work part time). 

The charity has a Conflict-of-Interest Policy for Trustees and Staff, and a register of interests is maintained for Trustees, the Chief Executive Officer and the Senior Leadership Team. Trustees are required to disclose all relevant interests to the Clerk to the Trustees and are required to withdraw from any decisions where an actual or potential conflict of interest may arise. Any individual with an interest in a matter being discussed at a meeting must immediately declare the interest to the meeting. The Chair of the meeting will then decide whether that individual will be entitled to vote on the matter. 

## **Grant Making** 

We recognise that our ability to fund research is limited by our physical and financial resources. We aim to maximise the impact of our grants by encouraging research which is likely to win support from larger funding bodies in due course. 

- “Charity Governance Code for Larger Charities” published by the Good Governance Steering Group 

- “The Essential Trustee”, published by the Charity Commission. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**25** 



We believe that there is great value is collaborative research. Finding a cure depends on the cooperation of many experts, some of whom may not have worked in primary bone cancer research to date. Therefore we place special emphasis on the importance of: 

- Creating the opportunity for researchers to work within primary bone cancer research 

- Nurturing the careers of early-stage researchers with an interest in primary bone cancer 

- Working with research teams to develop their research ideas through an innovative pilot grant scheme 

- Supporting proposals which are likely to win support from larger funding bodies 

- Encouraging collaboration between research groups 

- Encouraging interdisciplinary team work and partnerships 

- Facilitating access to primary tissue and clinical data 

- Working with other charities to fund research costs 

BCRT has established its grant making policy, which adheres to the recommendations set out by the Association of Medical Research Charities (AMRC) and National Institute for Health Research (NIHR) for peer review, to achieve its objects for the public benefit, and this policy is reviewed periodically. Applications are invited through calls for proposals, which then undergo a thorough review process including both review by our Independent Scientific Advisory Panel (ISAP) and external expert reviewers where necessary. The ISAP make recommendations to the trustees on the award of research grants, and the Board of Trustees approve the grants to be awarded. The ISAP consists of research professionals who are from respected centres of research throughout the UK and Europe. We also have one lay member of ISAP. BCRT is an active member of the AMRC. 

## The role of ISAP is to: 

- Assess the validity of all research applications, taking into account the results of the external peer review process 

- Interview candidates for studentships and fellowships 

- Make recommendations in respect of funding projects to the Board of Trustees. 

BCRT works with the primary bone cancer community and ISAP to develop our strategy to respond to areas of unmet or urgent need. BCRT works collaboratively with researchers and places emphasis on the ongoing monitoring of the impact of the research that we fund. 

## **Risk Management** 

The trustees have a duty to identify and review the risks to which the charity is exposed, and to ensure that appropriate controls are in place to provide reasonable assurance against fraud and error. BCRT has a risk management policy, which reflects the commitment of the trustees to maintaining a strong risk management framework. 

The trustees have examined the major strategic, business and operational risks which are faced by the charity, and confirm that there are suitable systems and procedures in place to enable those risks to be appropriately mitigated managed and monitored. The the CEO and Senior Leadership Team has a day to day responsibility to highlight any major risks that they may become aware of during the course of their duties. 

The majority of BCRT’s income is from voluntary donations and income from investments derived from voluntary contributions, and so there is a significant risk in being unable to maintain and grow income, in a cost-effective manner, in order to fund our charitable objectives and our 5-year strategy. To manage this risk, the charity continues to invest into the diversification of income streams and to reduce reliance on a small number of core sources of income. 

## **Volunteers** 

The trustees are very appreciative of the work carried out by numerous volunteers throughout the UK and overseas and thank them for their tireless work in organising fundraising activities. There are also many volunteers that have played a role in other BCRT activities such as office administration, supporting challenges and events, conferences and Bone Cancer Awareness Week. In accordance with accepted practice, no value has been included in the financial statements to reflect the work undertaken by volunteers. 

## **Financial Review** 

## **Income and Expenditure** 

BCRT celebrated it’s 15 year anniversary in 2021 by achieving the highest ever level of income at £4.673m. This is an increase of 70% on the previous year, and represents 20% of the total income generated since the charity was first registered in 2006. Despite the ongoing impact of the global pandemic we have continued to capitalise on virtual fundraising opportunities and engage with more new supporters, raising awareness of the signs and symptoms of primary bone cancer as well as raising funds. Many of our fundraisers have continued to organise fundraising activities during the pandemic. We have received grants and donations from a number of Trusts and Charitable Foundations, including a generous single donation of £1 million towards our research programme. We gratefully thank every single fundraiser who contributed in 2021, no matter how large or small – every donation makes such a difference in enabling BCRT to fulfil its charitable objectives. 

During the year we spent £2,260K on charitable activities, including awarding grants totalling £1,334K. Charitable spend has increased by £1,310K on 2020’s total as research programmes and other planned activities restarted as the global pandemic eased. Fundraising costs were £569K, 12% of total income. A surplus of £2,047K was generated in the year. 

## **Investment Policy** 

BCRT’s investment policy requires that there must be no direct investment into tobacco or vaping companies. The charity’s investments are held in a combination of fixed interest securities, UK and overseas equities and alternative investments. The funds are held in two portfolios and managed by Brewin Dolphin. The Portfolio number 1, which comprised 58% of the total fund at 31 December 2021, has an investment mandate of ‘income and capital growth with moderate investment risk’, whilst the mandate for Portfolio number 2, 42% of total value at year end, is ‘income and capital growth with low investment risk’. 

During 2021 Portfolio number 1 made a total return of +12.78%. this compared to a total return in the MSCI Balanced Index of +12.54%. The market value of the investment portfolio as at 31 December 2021 was £2,236,537. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**26** 



During 2021 the Portfolio number 2 made a total return of +7.08%. This compared to a total return in the MSCI Conservative Index of +6.89%. the market value of the investment portfolio as at 231 December 2021 was £1,614,169. 

## **Reserves Policy** 

BCRT has a policy of maintaining sufficient reserves to enable the charity to meet, as a minimum, its operational costs for six months, estimated to be £1,410,000. 

At the end of 2020 there was a designated reserve of £489,000 towards the costs associated with multi-year grants, including the second phase of funding for the ICONIC clinical study, and other charitable support and information costs. All of these cost were realised in 2021, leaving a balance of £nil. 

During the year the trustees approved the designation of £2,620,000 towards future grant costs, including £1,200,000 towards the Hamilton Programme of Osteosarcoma research, an Early Career fellowship award, clinical trial support grants, consortia and research meeting costs and other planned grant awards. The total funds designated at 31 December 2021 was £2,620,000, of which £1,075,000 was income restricted at the point of donation. 

Restricted reserves at 31 December 2021 were £1,652,514 whilst free reserves were £1,635,136. This exceeds the level required by the reserves policy. The trustees regularly monitor and review the reserves held within the context of the funds required to fulfil the objectives of the charity. 

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

## **Disclosure of information to auditor** 

Each of the trustees confirms that so far as they are aware, there is no relevant audit information of which the charity’s auditor is unaware. They have taken all the steps that they ought to have taken in order to make themselves aware of any relevant audit information and to establish that the charity’s auditor are aware of that information. 

Approved by order of the Board of Trustees on 30 September 2022 and signed on its behalf by **Roger Paul - trustee** 

## **Report of the Independent Auditors to the Trustees of Bone Cancer Research Trust** 

## **Opinion** 

## **Going Concern** 

The trustees believe that the charity is a “going concern” based on the current financial status, the ongoing funding streams, the planned expenditure and research strategy. 

## **Trustees Responsibility Statement** 

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charity SORP; 

- make judgements and estimates that are reasonable and prudent; 

- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business. 

We have audited the financial statements of Bone Cancer Research Trust (the ‘charity’) for the year ended 31st December 2021 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

In our opinion the financial statements: 

- give a true and fair view of the state of the charity’s affairs as at 31st December 2021 and of its incoming resources and application of resources, for the year then ended; 

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and 

- have been prepared in accordance with the requirements of the Charities Act 2011. 

## **Basis for opinion** 

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report.  We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**27** 



## **Conclusions relating to going concern** 

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. 

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. 

## **Other information** 

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. 

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. 

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.  We have nothing to report in this regard. 

## **Matters on which we are required to report by exception** 

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion: 

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or 

- sufficient accounting records have not been kept; or 

- • the financial statements are not in agreement with the accounting records and returns; or 

- we have not received all the information and explanations we require for our audit. 

## **Responsibilities of trustees** 

As explained more fully in the Trustees’ Responsibilities Statement, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. 

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so. 

## **Our responsibilities for the audit of the financial statements** 

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder. 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. 

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: 

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows: 

- The engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise noncompliance with applicable laws and regulations. 

- We identified the laws and regulations applicable to the charity through discussions with management, and from our commercial knowledge and experience of the sector. 

- We focused on specific laws and regulations which we considered may have a direct material effect on the accounts of the operations of the Charity, including the Charities Act 2011. 

- We assessed the extent of compliance with laws and regulations identified above through making enquiries of management and inspecting legal correspondence. 

- Identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**28** 



We assessed the susceptibility of the charity’s financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by: 

- Making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud. 

- Considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations. 

To address the risk of fraud through management bias and override of controls, we: 

- Performed analytical procedures to identify any unusual or unexpected relationships. 

- Identified and tested journal entries and identified any significant transactions that were unusual or outside the normal course of business. 

- Investigated the rationale behind significant or unusual transactions. 

- Challenged assumptions and judgements made by management in determining significant accounting estimates. 

In response to the risk of irregularities and noncompliance with laws and regulations, we designed audit procedures which included, but were not limited to: 

## **Use of our report** 

This report is made solely to the charity’s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity’s trustees those matters we are required to state to them in an auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed. 

Christopher Darwin FCA (Senior Statutory Auditor) For and on behalf of Thomas Coombs Limited Statutory Auditor Chartered Accountants 3365 The Pentagon Century Way Thorpe Park Leeds West Yorkshire LS15 8ZB 

Date: 30 September 2022 

- Agreeing financial statements disclosures to underlying supporting documentation. 

- Discussions with management of known or suspected instances of non-compliance with laws and regulations. 

- Reading the minutes of meetings of those charged with governance. 

- Reviewing correspondence with HMRC, relevant regulators including the Charities Commission and the charity’s legal advisors. 

At the completion stage of the audit, the engagement partner’s review included ensuring that the team had approached their work with appropriate professional scepticism and thus the capacity to identify noncompliance with laws and regulations and fraud. 

There are inherent limitations in the audit procedures described above and the further removed noncompliance of laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement relating to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment. 

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at www.frc.org.uk/ auditorsresponsibilities. This description forms part of our Report of the Independent Auditors. 



ANNUAL REPORT AND ACCOUNTS **2021** 

**29** 



## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31[ST] DECEMBER 2021** 

||**UNRESTRICTED**<br>**RESTRICTED TOTAL FUNDS TOTAL FUNDS**<br>**FUNDS**<br>**FUNDS**<br>**2021**<br>**2020**<br>~~**NOTES**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**INCOME AND ENDOWMENTS FROM**<br>Donations and legacies<br>2<br>2,655,762<br>1,952,988<br>4,608,750<br>2,718,008<br>Other trading activities<br>3<br>13,757<br>-<br>13,757<br>6,292<br>Investment income<br>4<br>50,516<br>-<br>50,516<br>31,742<br>**Total**<br>**2,720,035**<br>**1,952,988**<br>**4,673,023**<br>**2,756,042**<br>**EXPENDITURE ON**<br>Income generation<br>5<br>569,275<br>-<br>569,275<br>400,027<br>**Charitable activities**<br>6<br>Research<br>584,901<br>906,035<br>1,490,936<br>319,094<br>Awareness<br>534,302<br>-<br>534,302<br>449,377<br>Information<br>98,497<br>-<br>98,497<br>76,254<br>Support<br>87,575<br>34,528<br>122,103<br>94,977<br>Governance<br>13,752<br>-<br>13,752<br>9,952<br>**Total**<br>**1,888,302**<br>**940,563**<br>**2,828,865**<br>**1,349,681**<br>**NET INCOME/(EXPENDITURE)**<br>**BEFORE INVESTMENT GAINS/(LOSSES)**<br>831,733<br>1,012,425<br>1,844,158<br>1,406,361<br>Net gains on investments<br>203,075<br>-<br>203,075<br>33,991<br>**NET INCOME**<br>**1,034,808**<br>**1,012,425**<br>**2,047,233**<br>**1,440,352**<br>**RECONCILIATION OF FUNDS**<br>**Total funds brought forward**<br>2,172,436<br>640,089<br>2,812,525<br>1,372,173<br>**TOTAL FUNDS CARRIED FORWARD**<br>**3,207,244**<br>**1,652,514**<br>**4,859,758**<br>**2,812,525**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**30** 



## **STATEMENT OF FINANCIAL POSITION 31[ST] DECEMBER 2021** 

||**UNRESTRICTED**<br>**RESTRICTED TOTAL FUNDS TOTAL FUNDS**<br>**FUNDS**<br>**FUNDS**<br>**2021**<br>**2020**<br>~~**NOTES**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**FIXED ASSETS**<br>Intangible assets<br>13<br>6,463<br>-<br>6,463<br>-<br>Tangible assets<br>14<br>20,645<br>-<br>20,645<br>8,309<br>Investments<br>15<br>3,847,964<br>-<br>3,847,964<br>2,090,680<br>**3,875,072**<br>**-**<br>**3,875,072**<br>**2,098,989**<br>**CURRENT ASSETS**<br>Stocks<br>16<br>176,920<br>-<br>176,920<br>128,742<br>Debtors<br>17<br>437,491<br>-<br>437,491<br>224,174<br>Cash at bank and in hand<br>534,069<br>1,652,514<br>2,186,583<br>1,048,842<br>**1,148,480**<br>**1,652,514**<br>**2,800,994**<br>**1,401,758**<br>**CREDITORS**<br>Amounts falling due within one year<br>18<br>(1,286,617)<br>-<br>(1,286,617)<br>(669,408)<br>**NET CURRENT ASSETS**<br>**(138,137)**<br>**1,652,514**<br>**1,514,377**<br>**732,350**<br>**TOTAL ASSETS LESS CURRENT LIABILITIES**<br>3,736,935<br>1,652,514<br>5,389,449<br>2,831,339<br>**CREDITORS**<br>Amounts falling due after more than one year<br>19<br>(529,691)<br>-<br>(529,691)<br>(18,814)<br>**NET ASSETS**<br>**3,207,244**<br>**1,652,514**<br>**4,859,758**<br>**2,812,525**<br>**FUNDS**<br>21<br>Unrestricted funds<br>- Free reserves<br>1,635,136<br>1,675,127<br>- Fixed asset reserve<br>27,108<br>8,309<br>- Designated reserve<br>23<br>1,545,000<br>489,000<br>Restricted funds<br>22<br>1,652,514<br>640,089<br>**TOTAL FUNDS**<br>**4,859,758**<br>**2,812,525**|
|---|---|



The financial statements were approved by the Board of Trustees and authorised for issue on 30 September 2022 and were signed on its behalf by: 

## **Roger Paul - trustee** 


ANNUAL REPORT AND ACCOUNTS **2021** 

**31** 



## **STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31[ST] DECEMBER 2021** 

||~~**2021**~~<br>~~**2020**~~<br>~~**NOTES**~~<br>~~**£**~~<br>~~**£**~~<br>**Cash fows from operating activities:**<br>Cash generated from operations<br>1<br>2,665,267<br>1,237,873<br>**Net cash provided by operating activities**<br>**2,665,267**<br>**1,237,873**<br>**Cash fows from investing activities**<br>Purchase of intangible fxed assets<br>(6,600)<br>-<br>Purchase of tangible fxed assets<br>(17,233)<br>(318)<br>Purchase of fxed asset investments<br>(1,708,108)<br>(1,095,887)<br>Sale of fxed asset investments<br>153,899<br>322,255<br>Investment income<br>50,516<br>31,742<br>**Net cash used in investing activities**<br>**(1,527,526)**<br>**(742,208)**<br>**Change in cash and cash equivalents in the reporting period**<br>1,137,741<br>495,665<br>**Cash and cash equivalents at the beginning of the reporting period**<br>1,048,842<br>553,177<br>**Cash and cash equivalents at the end of the reporting period**<br>**2,186,583**<br>**1,048,842**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**32** 



## **NOTES TO THE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31[ST] DECEMBER 2021** 

## ~~**1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES**~~ 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Net income for the reporting period**<br>**(as per the Statement of Financial Activities)**<br>2,047,233<br>1,440,352<br>**Adjustments for:**<br>Depreciation charges<br>4,897<br>3,584<br>Gain on investments<br>(3,527)<br>(2,840)<br>Amortisation charges<br>137<br>5,048<br>Unrealised loss/(gain) on investments<br>(199,548)<br>(31,151)<br>Investment income<br>(50,516)<br>(31,742)<br>Increase in stocks<br>(48,178)<br>(76,338)<br>Increase in debtors<br>(213,317)<br>(4,885)<br>Increase/(decrease) in creditors<br>1,128,086<br>(64,155)<br>**Net cash provided by operations**<br>**2,665,267**<br>**1,237,873**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**33** 



## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31[ST] DECEMBER 2021** 

## **1. ACCOUNTING POLICIES** 

## **Basis of preparing the financial statements** 

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)’, Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets. 

The trustees consider that there are no material uncertainties about the Charity’s ability to continue for a period of not less than 12 months from the date of the approval of the financial statements. Accordingly the financial statements have been prepared on the going concern basis 

## **Income** 

Donations and sponsored events are included in the Statement of Financial Activities when: 

- the Charity is told it is to receive the gift or donation 

- the trustees are reasonably certain of the amount to be received 

- the trustees are reasonably certain they will receive the money and 

- any conditions for receipt are met 

Income from challenge events is recognised when the event takes place. Any income received in relation to events taking place in future years is held as deferred income until the event takes place. 

Legacies are recognised when it is probable that they will be received. Receipt is normally probable when: 

- there has been grant of a probate: 

- the executors have established that there are sufficient assets in the estate after settling any liabilities to pay the legacy; and 

- any conditions attached to the legacy are either within the control of the Charity or have been met. 

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the company will comply with conditions attaching to them and the grants will be received using the accruals model. 

No amounts are included in the financial statements for services donated by volunteers. 

Interest is accounted for on an accruals basis. 

## **Expenditure** 

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. 

Irrecoverable VAT is charged against the category of resources expended for which it was incurred. 

The costs of generating income consist of investment management fees and those costs incurred attracting voluntary income and activities for generating funds, such as events. 

Costs of charitable activities include grants made and an apportionment of overheads and administration costs. 

Grants payable are payments made to third parties in the furtherance of the charitable objectives of the Charity. Single or multi-year grants are accounted for where either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and any condition attaching to the grant is outside of the control of the Charity. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**34** 



Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to external inspection and legal fees together with an apportionment of overhead and administration costs. 

## **Critical accounting estimates and judgements** 

In the application of the charities accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. 

## **Critical estimates and judgements** 

## **Allocation of administration costs** 

Administration costs are allocated between the various activities of the group based on the weighting each activity has within total expenditure. The allocation of these costs is considered to be critical to the accounts because they have the ability to materially alter the allocation of costs between expenditure on raising funds and expenditure on charitable activities. 

The activities of the charity are categorised as follows: 

- expenditure incurred in order to raise funds for charitable purposes. 

Income generation expenditure incurred in order to raise funds for charitable purposes. Research – grant funding research into funding a cure for primary bone cancer. Awareness – increasing survival rates through raising awareness of primary bone cancer. Information – providing accurate and reliable information across all forms of primary bone cancer. Support –  improving the access to primary bone cancer support for all patients, family members, carers and friends. 

The breakdown of administration costs and how these were allocated between governance and other administration costs is based on the following rates: 

**Income generation 37.5% (2020: 29%) Information 6.7% (2020: 6%) Research 10.6% (2020: 24%) Support 8.9% (2020: 7%) Awareness 36.3% (2020: 34%)** 

In previous years, the costs of grants awarded, within research activities have been included when calculating the breakdown of administration costs. In 2021 the trustees decided that it would be appropriate to exclude grants awarded from this calculation to avoid significant year on year variances in the breakdown of administration costs. This approach will continue in future years. 

## **Intangible fixed assets** 

Amortisation is provided at the following annual rates in order to write off each asset over its estimated useful life. 

## **Website - 25% on cost** 

## **Tangible fixed assets** 

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Costs includes costs directly attributable to making the asset capable of operating as intended. 

Depreciation is provided to write off the cost less the estimated residual of tangible fixed assets by equal instalments over their estimated useful economic lives as follows: 

## **Fixtures and fittings** 

**- 25% on cost** 

## **Computer equipment  - 33% on cost and 25% on cost** 

## **Stocks** 

Stocks are valued at weighted average cost, after making due allowance for obsolete and slow moving items. 

## **Taxation** 

The charity is exempt from tax on its charitable activities. 

## **Fund accounting** 

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. 

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**35** 



Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. 

## **Investments** 

Investments held by the charity are shares which are publicly traded. Investments are recognised initially at fair value which is normally the transaction price including transaction costs. Subsequently, they are measured at fair value with changes recognised in ‘net gains / (losses) on investments’ in the SoFA. 

## **Financial instruments other than investments** 

The charity has financial assets and financial liabilities of a kind that qualify as basic and complex financial instruments. Basic financial instruments are measured at their settlement value in the case of current assets and liabilities and at discounted settlement value in the case of creditors falling due after more than one year. 

## **Status** 

The Bone Cancer Research Trust is a Charitable Incorporated Organisation (CIO), the liability is therefore restricted If the CIO is wound up, the members of the CIO have no liability to contribute to its assets and no personal responsibility for settling its debts and liabilities. 

## **Volunteers** 

The value of services provided by volunteers is not incorporated into these financial statements. Further details of the contribution made by volunteers can be found in the trustees’ annual report. 

Where services are provided to the Charity as a donation that would normally be purchased from a supplier, this contribution is included in the financial statements at an estimate based on the value of the contribution to the Charity. 

## **Pension costs** 

The Charity contributes to defined contribution schemes on behalf of some of its employees. These contributions are charged to the SoFA when accrued. 

## **2. DONATIONS AND LEGACIES** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Event income**<br>2,790,846<br>1,703,775<br>**Donations**<br>1,816,789<br>960,936<br>**Grants**<br>1,115<br>53,297<br>**Total**<br>**4,608,750**<br>**2,718,008**|
|---|---|



Grants received, included in the above, are as follows: 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Furlough grant**<br>1,115<br>53,297<br>**Total**<br>**1,115**<br>**53,297**|
|---|---|



## **3. OTHER TRADING ACTIVITIES** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Other trading income**<br>13,757<br>6,292<br>**Total**<br>**13,757**<br>**6,292**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**36** 



## **4. INVESTMENT INCOME** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Investment income**<br>50,516<br>31,742<br>**Total**<br>**50,516**<br>**31,742**|
|---|---|



## **5. INCOME GENERATION** 

Raising donations and legacies 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Staf costs**<br>234,934<br>209,635<br>**Event costs**<br>121,909<br>70,391<br>**Other trading costs**<br>6,561<br>3,108<br>**Other fundraising costs**<br>75,010<br>28,686<br>**Administration costs**<br>130,861<br>88,207<br>**Total**<br>**569,275**<br>**400,027**|
|---|---|



## **6. CHARITABLE ACTIVITIES COSTS** 

||**GRANT FUNDING OF**<br>**ADMINISTRATION**<br>**DIRECT COSTS**<br>**ACTIVITIES (SEE NOTE 7)**<br>**COSTS (SEE NOTE 8)**<br>**TOTALS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Research**<br>131,623<br>1,327,298<br>32,015<br>1,490,936<br>**Awareness**<br>425,022<br>-<br>109,280<br>534,302<br>**Information**<br>78,367<br>-<br>20,130<br>98,497<br>**Support**<br>95,405<br>-<br>26,698<br>122,103<br>**Governance**<br>-<br>-<br>13,752<br>13,752<br>**Total**<br>**730,417**<br>**1,327,298**<br>**201,875 2,259,590**<br>Total 2020<br>567,015<br>183,027<br>199,612<br>949,654|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**37** 



## **7. GRANTS AWARDED TO INSTITUTIONS IN THE YEAR** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Research**<br>1,327,298<br>183,027<br>**2021**<br>**2021**<br>**2021**<br>2020<br>**Unrestricted Restricted**<br>**Total**<br>Prof Sibylle Mittnacht, UCL Cancer Institute, Developing<br>Genome-informed treatment to improve outcome in Osteosarcoma<br>239,649<br>9,555<br>249,204<br>37,139<br>Dr William Cross UCL, Posthumous evaluation of a high-grade<br>widely disseminated chondrosarcoma through analysis<br>of its evolutionary history<br>-<br>-<br>-<br>70,000<br>Prof Paul Cool, Sample collection support - Oswestry<br>-<br>-<br>-<br>21,295<br>Dr Katie Finegan, University of Manchester, Targeting the<br>MEK5-ERK5 pathway<br>-<br>-<br>-<br>23,432<br>Dr Mark Morris, Research Institute of Health Science, University<br>of Wolverhampton, Identifcation of novel biomarkers for the<br>management of adamantinoma<br>-<br>-<br>-<br>21,000<br>Professor Alison Gartland, The Mellanby Centre<br>for Bone Research, Department of Oncology and Metabolism,<br>Shefeld University, The Role of Oestrogen in Chondrosarcoma<br>Using Patient-Derived Xenograft Mouse models: A Pilot Study<br>-<br>16,667<br>16,667<br>20,000<br>Prof Aykut Üren, Georgetown University, Lombardi<br>Comprehensive Cancer Centre, Second Generation<br>Clofarabine Derivatives as CD99 Inhibitors<br>-<br>70,000<br>70,000<br>-<br>Mr Jonathan Stevenson, The Royal National Orthopaedic<br>Hospital NHS Foundation Trust, Birmingham, sample<br>collection support<br>19,660<br>10,237<br>29,897<br>-<br>Prof Adrienne Flanagan, Royal National Orthopaedics Hospital<br>Brockley Hill, Stanmore, sample collection support<br>28,396<br>-<br>28,396<br>-<br>Prof Robert Falconer, Institute of Cancer Therapeutics, University<br>of Bradford, Development of a targeted methotrexate prodrug<br>with enhanced therapeutic index for osteosarcoma<br>-<br>16,626<br>16,626<br>-<br>Dr Darrell Green, Biomedical Research Centre, Norwich Medical<br>School,_TP53_Restoration using mRNA Vaccine Technology<br>11,000<br>9,000<br>20,000<br>-<br>Dr Karen Shah, The Mellanby Centre for Bone Research, Department<br>of Oncology and Metabolism, Shefeld University, Delineating the<br>role of hypoxic extracellular vesicles in pulmonary metabolism<br>-<br>19,867<br>19,867<br>-<br>Dr Kogularamanan Suntharalingam, School for Chemistry, University<br>of Leicester, Bone-seeking Metal-based Drugs to overcome<br>Chemotherapy Resistant Osteosarcoma Sub-populations<br>-<br>20,000<br>20,000<br>-<br>Professor Gareth Veal, Newcastle University, Optimising the<br>Treatment of Teenagers and Young Adults with Ewing Sarcoma<br>through an Increased Understanding of Clinical Pharmacology<br>and Toxicity Biomarker<br>-<br>145,530<br>145,530<br>-|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**38** 



_Continued…_ 

||||~~**2021**~~|~~**2020**~~|
|---|---|---|---|---|
||||~~**£**~~|~~**£**~~|
||**2021**|<br>**2021**|**2021**|2020|
||**Unrestricted**|**Restricted**|**Total**||
|Dr Sandra Strauss, UCL Cancer Institute, ICONIC – Improving<br>Outcome through Collaboration in Osteosarcoma|-|<br>175,000|175,000|-|
|Dr Olivier Pardo, Imperial College, Division of Cancer,<br>Modulation of Interferon Gamma-mediated Signalling and<br>immune Response by Fibroblast Growth Factor 2 in Osteosarcoma|173,013|<br>76,768|249,781|-|
|Dr Martin Pule, UCL Cancer Institute, Towards Engineered<br>T Cells for Osteosarcoma|4,000|<br>30,614|34,614|-|
|Dr Sandra Strauss, UCL Cancer Institute, Improving outcome<br>in Sarcoma through Analysis and interrogation of National<br>Cancer Data|43,082|<br>-|43,082|-|
|Dr Sandra Strauss, UCL Cancer institute, Euro Ewing Consortium|-|<br>36,091|36,091|-|
|Early Diagnosis Patient Grant|6,000|<br>-|6,000|-|
|Mr Kenneth Rankin, Northern Institute for Cancer Research,<br>Newcastle University, sample collection support|11,000|<br>5,000|16,000|-|
|Prof Susan Burchill, Leeds Institute of Medical Research,<br>International Collaboration to Optimise|-|<br>149,622|149,622|-|
|Patient Travel Support Grant|2,520|<br>-|2,520|2,201|
|Prof Sue Burchill, University of Leeds, Modelling Ewing’s sarcoma<br>heterogeneity and tumour microenvironment to improve outcomes|-|<br>-|-|(2,198)|
|Dr Helen Roberts (née Owen), Middlesex University London,<br>MicroRNA Regulation of Autophagy-Induced Chemoresistance<br>in Osteosarcoma|-|<br>-|-|(569)|
|Prof Sue Burchill, University of Leeds, Can we reliably detect viable,<br>dying or dead Ewing’s sarcoma cells in peri-tumoural tissue following<br>induction chemotherapy?|<br>-|<br>-|-|(1,902)|
|Prof Alison Gartland, The University of Shefeld, Osteo,<br>Purigenic signalling in osteosarcoma.<br>Professor Dominique Heymann, The University of Shefeld,<br>Osteo, Early events of recurrent disease and metastatic|-|<br>-|-|(2,131)|
|dissemination in osteosarcoma: pre-clinical assessment and|||||
|clinical proof-of-concept.|-|<br>-|-|(4)|
|Prof Sue Burchill, University of Leeds, Ewings Ideas, Identifcation|||||
|of the lead candidate NRXN1 isoform as a prognostic biomarker|||||
|and a novel target for therapy|-|<br>-|-|(4)|
|Grant refund - Dr Sandra Strauss, Investigation of CL67|||||
|as a frst-in-class novel inhibitor of the HIF 1alpha pathway|||||
|in osteosarcoma|-|<br>-|-|(5,232)|
|Dr Jessica Bates, University College London Hospital,|||||
|Ewing sarcoma project|(1,599)|<br>-|(1,599)|-|




ANNUAL REPORT AND ACCOUNTS **2021** 

**39** 



_Continued…_ 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**2021**<br>**2021**<br>**2021**<br>2020<br>**Unrestricted Restricted**<br>**Total**<br>**Restricted funding allocated to payments of existing grants**<br>**meeting the specifc restrictions**<br>**(115,458)**<br>**115,458**<br>**-**<br>**-**<br>**421,263**<br>**906,035 1,327,298**<br>**183,027**<br>**8. ADMINISTRATION COSTS**<br>**INVESTMENT**<br>**GOVERNANCE**<br>**MANAGEMENT**<br>**MANAGEMENT COSTS**<br>**COSTS**<br>**TOTALS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Research**<br>32,015<br>-<br>-<br>32,015<br>**Awareness**<br>109,280<br>-<br>-<br>109,280<br>**Information**<br>20,130<br>-<br>-<br>20,130<br>**Support**<br>26,698<br>-<br>-<br>26,698<br>**Income generation**<br>112,627<br>18,234<br>-<br>130,861<br>**Governance**<br>-<br>-<br>13,752<br>13,752<br>**Total**<br>**300,750**<br>**18,234**<br>**13,752**<br>**332,736**<br>Total 2020<br>268,639<br>9,228<br>9,952<br>287,819<br>**Administration costs, included in the above, are as follows:**<br>~~**RESEARCH**~~<br>~~**AWARENESS**~~<br>~~**INFORMATION**~~<br>~~**SUPPORT**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Wages**<br>7,157<br>24,426<br>4,499<br>5,966<br>**Social security**<br>584<br>1,993<br>367<br>487<br>**Pensions**<br>173<br>592<br>109<br>145<br>**Redundancy costs**<br>-<br>-<br>-<br>-<br>**Rent, rates and water**<br>2,541<br>8,672<br>1,597<br>2,118<br>**Telephone**<br>1,019<br>3,479<br>641<br>850<br>**Postage and stationery**<br>1,807<br>6,181<br>1,140<br>1,514<br>**Sundries**<br>1,672<br>5,710<br>1,052<br>1,395<br>**Travel and subsistence**<br>293<br>1,002<br>185<br>244<br>**Software licences**<br>2,864<br>9,772<br>1,800<br>2,387<br>**Recruitment and human resources costs**<br>1,579<br>5,387<br>992<br>1,316<br>**Stock management**<br>11,311<br>38,604<br>7,110<br>9,430<br>**Bank charges**<br>90<br>304<br>56<br>74<br>**Legal fees**<br>389<br>1,329<br>245<br>325<br>**Amortisation of intangible fxed assets**<br>15<br>50<br>9<br>12<br>**Depreciation of tangible fxed assets**<br>521<br>1,779<br>328<br>435<br>**Portfolio management**<br>-<br>-<br>-<br>-<br>**Trustees’ expenses and meeting costs**<br>-<br>-<br>-<br>-<br>**Auditors’ remuneration**<br>-<br>-<br>-<br>-<br>**Accountancy and legal fees**<br>-<br>-<br>-<br>-<br>**Total**<br>**32,015**<br>**109,280**<br>**20,130**<br>**26,698**<br>Total 2020<br>64,477<br>90,800<br>15,311<br>19,072|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**40** 



## _Continued…_ 

||**INCOME**<br>**2021 TOTAL**<br>**2020 TOTAL**<br>**GENERATION**<br>**GOVERNANCE**<br>**ACTIVITIES**<br>**ACTIVITIES**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Wages**<br>25,171<br>-<br>67,219<br>63,661<br>**Social security**<br>2,054<br>-<br>5,485<br>5,385<br>**Pensions**<br>610<br>-<br>1,629<br>1,359<br>**Redundancy costs**<br>-<br>-<br>-<br>4,295<br>**Rent, rates and water**<br>8,936<br>-<br>23,864<br>23,130<br>**Telephone**<br>3,585<br>-<br>9,574<br>9,771<br>**Postage and stationery**<br>6,383<br>-<br>17,025<br>14,060<br>**Sundries**<br>5,884<br>-<br>15,713<br>7,899<br>**Travel and subsistence**<br>1,032<br>-<br>2,756<br>3,845<br>**Software licences**<br>10,070<br>-<br>26,893<br>32,035<br>**Recruitment and human resources costs**<br>5,552<br>-<br>14,826<br>8,533<br>**Stock management**<br>39,781<br>-<br>106,326<br>82,987<br>**Bank charges**<br>314<br>-<br>838<br>785<br>**Legal fees**<br>1,370<br>-<br>3,658<br>2,261<br>**Amortisation of intangible fxed assets**<br>51<br>-<br>137<br>5,048<br>**Depreciation of tangible fxed assets**<br>1,834<br>-<br>4,897<br>3,585<br>**Portfolio management**<br>18,234<br>-<br>18,234<br>9,228<br>**Trustees’ expenses and meeting costs**<br>-<br>260<br>260<br>1,928<br>**Auditors’ remuneration**<br>-<br>9,100<br>9,100<br>5,319<br>**Accountancy and legal fees**<br>-<br>4,392<br>4,392<br>2,705<br>**Total**<br>**130,861**<br>**13,752**<br>**332,736**<br>**287,819**<br>Total 2020<br>88,207<br>9,952<br>287,819|
|---|---|



## **9. AUDITORS’ REMUNERATION** 

||~~**2021**~~|~~**2020**~~|
|---|---|---|
||~~**£**~~|~~**£**~~|
|**Fees payable to the charity’s auditors for the audit of the charity’s fnancial statements**|**9,100**|**5,319**|



## **10. TRUSTEES’ REMUNERATION AND BENEFITS** 

The average number of trustees in the year were 11 (2020: 13). 

There were no trustee’s remuneration or other benefits for the year ended 31st December 2021 nor for the year ended 31st December 2020. 

All trustees give their time freely and no trustee remuneration was paid in the year. During the year monetary donations made by trustees to the Charity totalled £668 (2020: £1,142). A number of trustees have connections to organisations which donate funds to the Trust. Further details are provided in note 24. 

## **Trustees’ expenses** 

Reimbursed expenses, which are all subject to the charity’s processes of internal controls, do not form part of the remuneration and are not included above. During the period, trustee expenses of £260 (2020: £1,634) were reimbursed to two trustees (2020: six trustees). 


ANNUAL REPORT AND ACCOUNTS **2021** 

**41** 



## **11. STAFF COSTS** 


**----- Start of picture text -----**<br>
||||
|---|---|---|
|2021|2020|
|£|£|
|Wages and salaries|592,469|526,537|
|Social security costs|52,529|45,088|
|Other pension costs|15,382|13,769|
|Redundancy costs|-|4,295|
|Total|660,380|589,689|

**----- End of picture text -----**<br>


## **The average monthly number of employees during the year was as follows:** 


**----- Start of picture text -----**<br>
||||
|---|---|---|
|2021|2020|
|Permanent staff|20|18|

**----- End of picture text -----**<br>


The average full time equivalent of employees during the year was 18.3 (2020: 17.4). 

No employees received emoluments in excess of £60,000. 

The Trust considers its key management personnel comprise the trustees and its Senior Management Team. The total employment costs to the charity of the key management personnel were £156,923 (2020: £141,609). 

## **12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** 


**----- Start of picture text -----**<br>
|||||
|---|---|---|---|
|UNRESTRICTED RESTRICTED|TOTAL|
|FUNDS|FUNDS|FUNDS|
|£|£|£|
|INCOME AND ENDOWMENTS FROM|
|Donations and legacies|2,148,648|569,360|2,718,008|
|Other trading activities|6,292|-|6,292|
|Investment income|31,742|-|31,742|
|Total|2,186,682|569,360|2,756,042|
|EXPENDITURE ON|
|Income generation|400,027|-|400,027|
|Charitable activities|
|Research|181,074|138,020|319,094|
|Awareness|429,377|20,000|449,377|
|Information|76,254|-|76,254|
|Support|23,624|71,353|94,977|
|Admin|9,952|-|9,952|
|Total|1,120,308|229,373|1,349,681|
|Net gains on investments|33,991|-|33,991|
|NET INCOME|1,100,365|339,987|1,440,352|
|RECONCILIATION OF FUNDS|
|Total funds brought forward|1,072,071|300,102|1,372,173|
|TOTAL FUNDS CARRIED FORWARD|2,172,436|640,089|2,812,525|

**----- End of picture text -----**<br>



ANNUAL REPORT AND ACCOUNTS **2021** 

**42** 



## **13. INTANGIBLE FIXED ASSETS** 

||~~**WEBSITE COSTS**~~<br>~~**£**~~<br>**COST**<br>At 1st January 2021<br>38,187<br>Additions<br>6,600<br>**At 31st December 2021**<br>**44,787**<br>**AMORTISATION**<br>At 1st January 2021<br>38,187<br>Charge for year<br>137<br>**At 31st December 2021**<br>**38,324**<br>**NET BOOK VALUE**<br>**At 31st December 2021**<br>**6,463**<br>At 31st December 2020<br>-|
|---|---|



## **14. TANGIBLE FIXED ASSETS** 

||**FIXTURES AND**<br>**COMPUTER**<br>**FITTINGS**<br>**EQUIPMENT**<br>**TOTALS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**COST**<br>At 1st January 2021<br>11,488<br>20,075<br>31,563<br>Additions<br>384<br>16,849<br>17,233<br>**At 31st December 2021**<br>**11,872**<br>**36,924**<br>**48,796**<br>**DEPRECIATION**<br>At 1st January 2021<br>4,432<br>18,822<br>23,254<br>Charge for year<br>2,562<br>2,335<br>4,897<br>**At 31st December 2021**<br>**6,994**<br>**21,157**<br>**28,151**<br>**NET BOOK VALUE**<br>**At 31st December 2021**<br>**4,878**<br>**15,767**<br>**20,645**<br>At 31st December 2020<br>7,056<br>1,253<br>8,309|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**43** 



## **15. FIXED ASSET INVESTMENTS** 

||**LISTED**<br>**CASH AND**<br>**INVESTMENTS**<br>**SETTLEMENTS PENDING**<br>**TOTALS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**MARKET VALUE**<br>At 1st January 2021<br>2,036,771<br>53,909<br>2,090,680<br>Additions<br>1,716,470<br>(8,362)<br>1,708,108<br>Disposals<br>(150,372)<br>-<br>(150,372)<br>Revaluations<br>199,548<br>-<br>199,548<br>**At 31st December 2021**<br>**3,802,417**<br>**45,547**<br>**3,847,964**<br>**NET BOOK VALUE**<br>**At 31st December 2021**<br>**3,802,417**<br>**45,547**<br>**3,847,964**<br>At 31st December 2020<br>2,036,771<br>53,909<br>2,090,680|
|---|---|



At 31st December 2021 no individual investment represented more than 5% of the total investment portfolio valuation. 

The historical cost at 31st December 2021 is £3,392,375 (2020: £1,807,333). 

All investments are carried at their fair value. Investment in equities and fixed interest securities are all traded in quoted public markets, primarily the London Stock Exchange. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value). 

The significance of financial instruments to the ongoing financial sustainability of the Trust is considered in the financial review and investment policy and performance sections of the Trustees’ Annual Report. 

The main risk to the Charity from financial instruments arises from uncertain investment markets resulting in variable income and capital returns from the portfolio of assets. 

Currency translation risks remain for those companies and bonds that are exposed to overseas earnings and assets. 

Liquidity risk is anticipated to be low as all assets are traded on recognised exchanges with good liquidity and high trading volumes. The Charity’s portfolio has no material investment holdings in markets subject to exchange controls or trading restrictions. 

The Charity manages investment risk by appointing professional investment managers and operating an investment policy that provides for a high degree of diversification of holdings within investment asset classes that are quoted on recognised stock exchanges. 

The Charity does not make use of derivatives and similar complex financial instruments as it takes the view that investments are held for their longer term total return. 

## **16. STOCKS** 

||~~**2021**~~|~~**2020**~~|
|---|---|---|
||~~**£**~~|~~**£**~~|
|**Stocks of fund raising items**|176,920|128,742|




ANNUAL REPORT AND ACCOUNTS **2021** 

**44** 



## **17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Other debtors**<br>25,710<br>21,051<br>**Accrued income, including gift aid receivable**<br>138,968<br>117,983<br>**Prepaid event costs**<br>272,813<br>85,140<br>**Total**<br>**437,491**<br>**224,174**|
|---|---|



## **18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Trade creditors**<br>49,266<br>5,532<br>**Taxation and social security**<br>19,012<br>13,567<br>**Grants payable**<br>1,134,977<br>617,720<br>**Deferred event income**<br>23,293<br>5,876<br>**Other creditors**<br>60,069<br>26,713<br>**Total**<br>**1,286,617**<br>**669,408**|
|---|---|



## **19. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR** 

||~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>**Grants payable**<br>529,691<br>18,814<br>**Reconciliation of Grants Awarded**<br>**2021**<br>**2020**<br>Opening liability obligation<br>636,534<br>670,229<br>Research grants awarded in the year<br>1,327,298<br>195,067<br>Research grants refunded in the year<br>-<br>(5,232)<br>Provisions no longer required<br>(1,599)<br>(6,808)<br>Paid during the year<br>(299,164)<br>(216,722)<br>**Closing liability obligation**<br>**1,664,668**<br>**636,534**<br>**Split as:**<br>**Due within one year**<br>1,134,977<br>617,720<br>**Due after more than one year**<br>529,691<br>18,814|
|---|---|



## **20. LEASING AGREEMENTS** 

The following operating lease payments are committed to be paid: 

||~~**LAND AND BUILDINGS**~~<br>~~**OTHER**~~<br>~~**2021**~~<br>~~**2020**~~<br>~~**2021**~~<br>~~**2020**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Expiring:**<br>**Within one year**<br>16,797<br>16,797<br>818<br>6,161<br>**Between one and fve years**<br>18,324<br>35,121<br>576<br>1,394<br>**Total**<br>**35,121**<br>**51,918**<br>**1,394**<br>**7,555**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**45** 



## **21. MOVEMENT IN FUNDS** 

||**NET MOVEMENT**<br>**AT 1/1/21**<br>**IN FUNDS**<br>**31/12/21**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Unrestricted funds**<br>**General fund**<br>2,172,436<br>1,034,808<br>3,207,244<br>**Restricted funds**<br>**Ewing Sarcoma**<br>Liberty’s Legacy<br>188,055<br>872<br>188,927<br>Frank’s Fund<br>144,136<br>(35,098)<br>109,038<br>Freddie’s Future<br>36,045<br>15,425<br>51,470<br>Fitzy’s Fund<br>41,979<br>58,058<br>100,037<br>Ewing Sarcoma Research Trust<br>22,198<br>(20,000)<br>2,198<br>Other funds restricted to research into Ewing Sarcoma<br>39,047<br>3,415<br>42,462<br>**Osteosarcoma**<br>Hamilton Family Research Fund<br>-<br>1,079,500<br>1,079,500<br>In support of Mary Collard<br>27,748<br>(27,427)<br>321<br>Tom Stead<br>7,687<br>(2,788)<br>4,899<br>Anthony Pilcher Bone Cancer Trust<br>5,973<br>(5,855)<br>118<br>Jess Gower<br>3,241<br>(3,183)<br>58<br>Tom Hunt<br>2,711<br>10,663<br>13,374<br>Rhodri Jones<br>6,125<br>(6,013)<br>112<br>Other funds restricted to research into Osteosarcoma<br>10,911<br>(10,419)<br>492<br>**Other**<br>**Research**<br>The Liz Clarke-Saul Fund<br>10,473<br>13,099<br>23,572<br>Michael Davie Research Foundation<br>-<br>-<br>-<br>Robert Luf Foundation<br>-<br>-<br>-<br>Other funds restricted to research<br>435<br>(7,659)<br>(7,224)<br>**Infrastructure Grant**<br>QBE Foundation<br>737<br>(737)<br>-<br>PF Charitable Trust<br>11,000<br>-<br>11,000<br>Doris Field Charitable Trust<br>7,500<br>(2,500)<br>5,000<br>Barbour Foundation<br>-<br>-<br>-<br>Edward Cadbury Trust<br>5,000<br>(5,000)<br>-<br>GJW Turner Charitable Trust<br>-<br>2,500<br>2,500<br>Margaret Butters Reekie<br>10,000<br>(10,000)<br>-<br>Other funds restricted to infrastructure grants<br>1,242<br>7,000<br>8,242<br>**Methotraxate Prodrug**<br>Balcombe Trust<br>10,000<br>(10,000)<br>-<br>The Charity of Stella Symons<br>10,000<br>(10,000)<br>-<br>**Support, Information and Awareness**<br>Takeda<br>20,727<br>(12,352)<br>8,375<br>My Blue Heart<br>4,309<br>(4,309)<br>-<br>James Tudor Foundation<br>7,100<br>(1,458)<br>5,642<br>February Foundation<br>-<br>-<br>-<br>St James’ Place<br>2,500<br>(2,500)<br>-<br>David Brooke Foundation<br>-<br>2,403<br>2,403<br>Other funds restricted to support, information and awareness<br>3,210<br>(3,212)<br>(2)<br>**640,089**<br>**1,012,425**<br>**1,652,514**<br>**TOTAL FUNDS**<br>**2,812,525**<br>**2,047,233**<br>**4,859,758**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**46** 



## **21. MOVEMENT IN FUNDS - CONTINUED** 

Net movement in funds, included in the above are as follows: 

||**INCOMING**<br>**RESOURCES**<br>**GAINS AND**<br>**MOVEMENT**<br>**RESOURCES**<br>**EXPENDED**<br>**LOSSES**<br>**IN FUNDS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Unrestricted funds**<br>**General fund**<br>2,720,035<br>(1,888,302)<br>203,075<br>1,034,808<br>**Restricted funds**<br>**Ewing Sarcoma**<br>Liberty’s Legacy<br>135,872<br>(135,000)<br>-<br>872<br>Frank’s Fund<br>95,993<br>(131,091)<br>-<br>(35,098)<br>Freddie’s Future<br>65,425<br>(50,000)<br>-<br>15,425<br>Fitzy’s Fund<br>113,588<br>(55,530)<br>-<br>58,058<br>Ewing Sarcoma Research Trust<br>14,963<br>(34,963)<br>-<br>(20,000)<br>Other funds restricted to research into Ewing Sarcoma<br>33,036<br>(29,621)<br>-<br>3,415<br>**Osteosarcoma**<br>Hamilton Family Research Fund<br>1,250,000<br>(170,500)<br>-<br>1,079,500<br>In support of Mary Collard<br>58,087<br>(85,514)<br>-<br>(27,427)<br>Tom Stead<br>16,096<br>(18,884)<br>-<br>(2,788)<br>Anthony Pilcher Bone Cancer Trust<br>9,545<br>(15,400)<br>-<br>(5,855)<br>Jess Gower<br>8,045<br>(11,228)<br>-<br>(3,183)<br>Tom Hunt<br>-<br>10,663<br>-<br>10,663<br>Rhodri Jones<br>8,587<br>(14,600)<br>-<br>(6,013)<br>Other funds restricted to research into Osteosarcoma<br>39,810<br>(50,229)<br>-<br>(10,419)<br>**Other Research**<br>The Liz Clarke-Saul Fund<br>13,099<br>-<br>-<br>13,099<br>Michael Davie Research Foundation<br>10,000<br>(10,000)<br>-<br>-<br>Robert Luf Foundation<br>10,000<br>(10,000)<br>-<br>-<br>Other funds restricted to research<br>16,742<br>(24,401)<br>-<br>(7,659)<br>**Infrastructure Grant**<br>QBE Foundation<br>-<br>(737)<br>-<br>(737)<br>PF Charitable Trust<br>10,000<br>(10,000)<br>-<br>-<br>Doris Field Charitable Trust<br>2,000<br>(4,500)<br>-<br>(2,500)<br>Barbour Foundation<br>5,000<br>(5,000)<br>-<br>0<br>Edward Cadbury Trust<br>-<br>(5,000)<br>-<br>(5,000)<br>GJW Turner Charitable Trust<br>5,000<br>(2,500)<br>-<br>2,500<br>Margaret Butters Reekie<br>-<br>(10,000)<br>-<br>(10,000)<br>Other funds restricted to infrastructure grants<br>9,000<br>(2,000)<br>-<br>7,000<br>**Methotrexate Prodrug**<br>Balcombe Trust<br>10,000<br>(20,000)<br>-<br>(10,000)<br>The Charity of Stella Symons<br>-<br>(10,000)<br>-<br>(10,000)<br>**Support, Information and Awareness**<br>Takeda<br>-<br>(12,352)<br>-<br>(12,352)<br>My Blue Heart<br>-<br>(4,309)<br>-<br>(4,309)<br>James Tudor Foundation<br>-<br>(1,458)<br>-<br>(1,458)<br>February Foundation<br>5,000<br>(5,000)<br>-<br>-<br>St James’ Place<br>2,500<br>(5,000)<br>-<br>(2,500)<br>David Brooke Foundation<br>2,600<br>(197)<br>-<br>2,403<br>Other funds restricted to support, information and awareness<br>3,000<br>(6,212)<br>-<br>(3,212)<br>**1,952,988**<br>**(940,563)**<br>**-**<br>**1,012,425**<br>**TOTAL FUNDS**<br>**4,673,023**<br>**(2,828,865)**<br>**203,075**<br>**2,047,233**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**47** 



## **21. MOVEMENT IN FUNDS - CONTINUED** 

||**NET MOVEMENT**<br>**AT 1/1/20**<br>**IN FUNDS**<br>**31/12/20**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Unrestricted funds**<br>**General fund**<br>1,072,071<br>1,100,365<br>2,172,436<br>**Restricted funds**<br>**Ewing sarcoma**<br>Liberty’s Legacy<br>109,798<br>78,257<br>188,055<br>Frank’s Fund<br>81,934<br>62,202<br>144,136<br>Freddie’s Future<br>-<br>36,045<br>36,045<br>Fitzy’s Fund<br>-<br>41,979<br>41,979<br>Ewing Sarcoma Research Trust<br>2,198<br>20,000<br>22,198<br>Other funds restricted to research into Ewing Sarcoma<br>23,333<br>15,714<br>39,047<br>**Osteosarcoma**<br>Hamilton Family Research Fund<br>-<br>-<br>In support of Mary Collard<br>725<br>27,023<br>27,748<br>Tom Stead<br>786<br>6,901<br>7,687<br>Anthony Pilcher Bone Cancer Trust<br>100<br>5,873<br>5,973<br>Jess Gower<br>-<br>3,241<br>3,241<br>Tom Hunt<br>13,149<br>(10,438)<br>2,711<br>Rhodri Jones<br>20<br>6,105<br>6,125<br>Other funds restricted to research into Osteosarcoma<br>2,013<br>8,898<br>10,911<br>**Other Research**<br>The Liz Clarke-Saul Fund<br>22,498<br>(12,025)<br>10,473<br>Michael Davie Research Foundation<br>-<br>-<br>-<br>Robert Luf Foundation<br>-<br>-<br>-<br>Other funds restricted to research<br>2,794<br>(2,359)<br>435<br>**Infrastructure Grant**<br>QBE Foundation<br>13,027<br>(12,290)<br>737<br>PF Charitable Trust<br>1,000<br>10,000<br>11,000<br>Doris Field Charitable Trust<br>5,000<br>2,500<br>7,500<br>Barbour Foundation<br>-<br>0<br>-<br>Edward Cadbury Trust<br>-<br>5,000<br>5,000<br>GJW Turner Charitable Trust<br>-<br>0<br>-<br>Margaret Butters Reekie<br>-<br>10,000<br>10,000<br>Other funds restricted to infrastructure grants<br>1,000<br>242<br>1,242<br>**Methotrexate Prodrug**<br>Balcombe Trust<br>-<br>10,000<br>10,000<br>The Charity of Stella Symons<br>-<br>10,000<br>10,000<br>**Support, Information and Awareness**<br>Takeda<br>20,727<br>-<br>20,727<br>My Blue Heart<br>-<br>4,309<br>4,309<br>James Tudor Foundation<br>-<br>7,100<br>7,100<br>February Foundation<br>-<br>-<br>-<br>St James’ Place<br>-<br>2,500<br>2,500<br>David Brooke Foundation<br>-<br>-<br>-<br>Other funds restricted to support, information and awareness<br>-<br>3,210<br>3,210<br>**300,102**<br>**339,987**<br>**640,089**<br>**TOTAL FUNDS**<br>**1,372,173**<br>**1,440,352**<br>**2,812,525**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**48** 



## **21. MOVEMENT IN FUNDS - CONTINUED** 

Net movement in funds, included in the above are as follows: 

||**INCOMING**<br>**RESOURCES**<br>**GAINS AND**<br>**MOVEMENT**<br>**RESOURCES**<br>**EXPENDED**<br>**LOSSES**<br>**IN FUNDS**<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Unrestricted funds**<br>**General fund**<br>2,186,682<br>(1,120,308)<br>33,991<br>1,100,365<br>**Restricted funds**<br>**Ewing sarcoma**<br>Liberty’s Legacy<br>85,725<br>(7,468)<br>-<br>78,257<br>Frank’s Fund<br>72,139<br>(9,937)<br>-<br>62,202<br>Freddie’s Future<br>36,045<br>-<br>-<br>36,045<br>Fitzy’s Fund<br>41,979<br>-<br>-<br>41,979<br>Ewing Sarcoma Research Trust<br>20,000<br>-<br>-<br>20,000<br>Other funds restricted to research into Ewing Sarcoma<br>15,714<br>-<br>-<br>15,714<br>**Osteosarcoma**<br>Hamilton Family Research Fund<br>-<br>-<br>-<br>-<br>In support of Mary Collard<br>50,992<br>(23,969)<br>-<br>27,023<br>Tom Stead<br>9,901<br>(3,000)<br>-<br>6,901<br>Anthony Pilcher Bone Cancer Trust<br>5,873<br>-<br>-<br>5,873<br>Jess Gower<br>3,241<br>-<br>-<br>3,241<br>Tom Hunt<br>-<br>(10,438)<br>-<br>(10,438)<br>Rhodri Jones<br>11,105<br>(5,000)<br>-<br>6,105<br>Other funds restricted to research into Osteosarcoma<br>14,068<br>(5,170)<br>-<br>8,898<br>**Other Research**<br>The Liz Clarke-Saul Fund<br>32,407<br>(44,432)<br>-<br>(12,025)<br>Michael Davie Research Foundation<br>-<br>-<br>-<br>-<br>Robert Luf Foundation<br>-<br>-<br>-<br>-<br>Other funds restricted to research<br>10,957<br>(13,316)<br>-<br>(2,359)<br>**Infrastructure Grant**<br>QBE Foundation<br>-<br>(12,290)<br>-<br>(12,290)<br>PF Charitable Trust<br>10,000<br>-<br>-<br>10,000<br>Doris Field Charitable Trust<br>2,500<br>-<br>-<br>2,500<br>Barbour Foundation<br>-<br>-<br>-<br>-<br>Edward Cadbury Trust<br>5,000<br>-<br>-<br>5,000<br>GJW Turner Charitable Trust<br>-<br>-<br>-<br>-<br>Margaret Butters Reekie<br>10,000<br>-<br>-<br>10,000<br>Other funds restricted to infrastructure grants<br>3,240<br>(2,998)<br>-<br>242<br>**Methotrexate Prodrug**<br>Balcombe Trust<br>10,000<br>-<br>-<br>10,000<br>The Charity of Stella Symons<br>10,000<br>-<br>-<br>10,000<br>**Support, Information and Awareness**<br>Takeda<br>-<br>-<br>-<br>-<br>My Blue Heart<br>4,309<br>-<br>-<br>4,309<br>James Tudor Foundation<br>7,100<br>-<br>-<br>7,100<br>February Foundation<br>-<br>-<br>-<br>-<br>St James’ Place<br>2,500<br>-<br>-<br>2,500<br>David Brooke Foundation<br>-<br>-<br>-<br>-<br>Other funds restricted to support, information and awareness 94,565<br>(91,355)<br>-<br>3,210<br>**569,360**<br>**(229,373)**<br>**-**<br>**339,987**<br>**TOTAL FUNDS**<br>**2,756,042**<br>**(1,349,681)**<br>**33,991**<br>**1,440,352**|
|---|---|




ANNUAL REPORT AND ACCOUNTS **2021** 

**49** 



## **22. RESTRICTED FUNDS** 

## **Ewing Sarcoma** 

The Liberty’s Legacy Restricted Fund represents monies restricted for research into Ewing Sarcoma. 

Franks fund represent monies restricted for research into Ewing Sarcoma. 

Freddie’s Future Restricted Fund represents monies restricted for research into Ewing Sarcoma. 

Fitzy’s Fund represents monies restricted for research into Ewing Sarcoma. 

The Ewing’s Sarcoma Research Trust Restricted Fund represents monies restricted for research into Genotype and Phenotype Self-renewing cancer-initiating Ewing Sarcoma, the National Ewing Sarcoma Multi-Disciplinary Team Meeting and oncolytic virus therapy for Ewing sarcoma. 

Other funds represent monies restricted for research into Ewing Sarcoma. 

## **Osteosarcoma** 

The Hamilton Family Research Fund represents funds restricted for research into Osteosarcoma. 

The Mary Collard Restricted Fund represents funds restricted for research into Osteosarcoma. 

The Tom Stead Restricted Fund represents monies restricted for research into Osteosarcoma. 

The Anthony Pilcher Restricted Fund represents monies restricted for research into Osteosarcoma. 

The Jess Gower Restricted Fund represents monies restricted for research into Osteosarcoma. 

The Tom Hunt Restricted Fund represents monies restricted for research into Osteosarcoma. 

The Rhodri Jones Restricted Fund represents monies restricted for research into Osteosarcoma Other funds represent monies restricted for research into Osteosarcoma. 

## **Infrastructure grant** 

The QBE Foundation Restricted Fund represents monies restricted to the 2018 Birmingham Infrastructure Grant. 

The PF Charitable Trust Fund represents monies restricted to the Oxford Infrastructure Grant. 

The Doris Field Charitable Trust represents monies restricted to the Oxford Infrastructure Grant. 

The Edwards Cadbury Trust represents monies restricted to the Birmingham Infrastructure Grant. 

The GJW Turner Charitable Trust represents monies restricted to the Birmingham Infrastructure Grant. 

The Miss Margaret Butters Reekie Charitable Trust represents monies restricted to the ICONIC research programme. Other funds represent monies restricted to Infrastructure grants. 

## **Methotrexate prodrug** 

The Balcombe Trust Fund represents monies restricted to the PhD awarded by BCRT in 2018 seeking to develop a targeted methotrexate prodrug. 

The Charity of Stella Symons represents monies restricted to the PhD awarded by BCRT in 2018 seeking to develop a targeted methotrexate prodrug 

## **Other research** 

The Liz Clarke-Saul Fund represents monies restricted for research into adamantinoma. 

Other funds represent monies restricted to research. 

## **Non research** 

The Takeda Restricted Fund represents monies restricted to the BCRT annual patient conference 

The My Blue Heart fund represents monies restricted to support. 

The James Tudor Foundation fund represents monies restricted to a patient amputation resource 

Other funds represent monies restricted to non-research charitable activities. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**50** 



## **23. DESIGNATED FUNDS** 

||~~**AT 1/1/21**~~<br>~~**PAID**~~<br>~~**DESIGNATED**~~<br>~~**AT 31/12/21**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>~~**£**~~<br>**Patient support grants**<br>29,000<br>(29,000)<br>**Infrastructure grants**<br>67,000<br>(67,000)<br>160,000<br>160,000<br>**ICONIC Grant**<br>175,000<br>(175,000)<br>**Information and awareness charitable activities**<br>43,000<br>(43,000)<br>70,000<br>70,000<br>**Early careers fellowship**<br>-<br>-<br>500,000<br>500,000<br>**Clinical Trial Support grants**<br>-<br>-<br>150,000<br>150,000<br>**Consortia and Research Meeting grants**<br>-<br>-<br>240,000<br>240,000<br>**Hamilton Programme of Osteosarcoma Research**<br>-<br>-<br>125,000<br>125,000<br>**Other grants**<br>175,000<br>(175,000)<br>300,000<br>300,000<br>**TOTAL FUNDS**<br>**489,000**<br>**(489,000)**<br>**1,545,000**<br>**1,545,000**|
|---|---|



Our patient support grants are available to help with the additional costs that a diagnosis of bone cancer and subsequent treatment can bring. 

Infrastructure grants support tissue collection at treatment centres across the UK. 

The ICONIC programme supports the collection of tissue samples from osteosarcoma patients, with the aim of improving future outcomes. 

Information and awareness charitable activities support planned patient advocacy and the creation and distribution of targeted information resources. 

Early career fellowship grants will ensure that future leaders in the field are able to create their own programme of research. 

Our Clinical Trial Support Grants will provide additional support to ongoing clinical trials, ensuring no stone is left unturned and every opportunity is explored for maximum patient benefit. 

In recognition of the need to bring the primary bone cancer research and clinical communities together, our new Consortia and Research Meeting Grants will bring about new levels of international collaboration and stimulate partnership working, accelerating progress. 

Hamilton Programme of Osteosarcoma Research is is aimed at supporting a programme of research, which will come together to make progress and improve outcomes for patients. 

Other designated grant funds relate to unrestricted grant funding to support a range of projects throughout 2022. 

## **24. RELATED PARTY DISCLOSURES** 

Trustees are required to disclose all relevant interests and register them with the Clerk to the Trustees and in accordance with the Charity’s policy to withdraw from decisions where a conflict of interest arises. 

Any individual with an interest in a matter being discussed at a meeting must declare the interest to the meeting. The chairman of the meeting will then decide whether that individual should withdraw during the discussion and, if not, whether the individual should be entitled to vote on the matter under discussion. 

During the year ended 31st December 2021, consultancy services of £1,170 (2020: 1,620) were provided by Sarah B Dawson Limited, a company in which one of the trustees to the charity, Sarah B Dawson is also a director. 

## **25. COMMITMENTS** 

As at 31 December 2021 the charity has committed to funding further research grants of £120,895. These commitments are subject to conditions and review within the control of the charity and accordingly not recognised as grant liabilities within notes 18 and 19. 


ANNUAL REPORT AND ACCOUNTS **2021** 

**51** 





## **©Bone Cancer Research Trust 2022** 

10 Feast Field, Horsforth, Leeds LS18 4TJ 

bcrt.org.uk 0113 258 5934 

@BCRT /BoneCancerResearchTrust 

@bonecancerresearch 

Also available **THE BIGGEST EVER COMMITMENT TO PRIMARY BONE CANCER. OUR STRATEGY 2017 – 2022** 

## and 

**LIVING WITH, AND BEYOND, PRIMARY BONE CANCER** 

Please contact us to request your free copy or visit our website for a printable / downloadable version. 



Registered charity in England & Wales: 1159590